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ABSTRACT 
 
Verma, Neal Raj. M.S., Department of Neuroscience, Cell Biology and Physiology, 
Wright State University, 2016. The Timing of Fluoxetine, Simvastatin and Ascorbic 
Acid Administration in a Post-Ischemic Stroke Environment Affects Infarct Volume 
and Hemorrhagic Transformation Frequency. 
 
 
 
Previous animal experiments have indicated that administration of 
fluoxetine and simvastatin at 20-26 hours post-stroke decreases the volume of 
ischemic infarcts. This experiment expanded on previous experiments by adding 
ascorbic acid to the post-stroke regimen, initiating simvastatin pre-stroke, and 
adding a third initiation time frame (48-54 hours). 
Male retired breeder Sprague-Dawley rats were on simvastatin for 7 days 
prior to stroke induction. Combined medications of 5 milligrams/kilogram of 
fluoxetine, 1 milligram/kilogram of simvastatin and 20 milligrams/kilogram of 
ascorbic acid were orally administered at 6-12 hours, 20-26 hours, or 48-54 hours, 
respectively, following stroke induction.  
Adult rats that were treated 20-26 hours post-stroke showed a decrease in 
infarct volume (15.67 ± 5.622 millimeters cubed, P=0.0098) compared to the 
control.  The combination of simvastatin, fluoxetine and ascorbic acid decreased the 
relative risk (RR=0.3704 (95% confidence interval 0.0987 to 1.3905, p-value = 
0.1411) of bleeding after ischemic stroke if initiated 20-26 hours after stroke 
induction in rats.  
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I.	INTRODUCTION	
STROKES	
	 In	medical	terminology,	a	stroke	is	defined	as	a	loss	of	blood	flow	to	brain	
tissue	(National	Stroke	Association	(NSA),	2016).	Blood	carries	vital	nutrients,	
including	oxygen,	to	brain	tissue.	When	brain	tissue	is	denied	blood,	it	dies,	and	
the	abilities	that	were	under	control	of	that	particular	area	of	the	brain	are	lost.	
The	functions	of	the	brain	are	localized	to	various	areas	within	the	brain,	and	the	
abilities	that	are	lost	after	a	stroke	typically	correlate	to	the	location	of	the	
stroke	and	the	amount	of	brain	tissue	that	dies	(NSA	2016).			
Statistically,	strokes	are	a	devastating	affliction	on	the	American	
population.	Every	year,	800,000	people	will	experience	a	stroke	(new	or	
recurrent).	Strokes	are	the	fifth	leading	cause	of	death	in	the	United	States,	and	
they	are	the	leading	cause	of	disability	(NSA	2016).	Broken	down	by	gender,	
40%	of	stroke	deaths	are	in	males	and	60%	are	in	females	(American	Heart	
Association	(AHA)/American	Stroke	Association	(ASA)	2016).	There	are	many	
risk	factors	that	predispose	individuals	to	strokes.	They	include	being	
overweight,	a	lack	of	physical	activity,	consuming	large	quantities	of	alcohol	and	
the	use	of	cocaine	or	methamphetamines	(Mayo	Clinic	2016).	Because	strokes	
are	frequently	permanently	disabling,	there	is	a	tremendous	need	for	research	
into	post‐stroke	care.	Specifically,	the	ability	to	rapidly	accelerate	neuro‐
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regeneration	could	prove	to	be	conducive	to	an	individual’s	recovery,	both	in	
terms	of	the	abilities	that	can	be	regained	and	the	amount	time	it	takes	to	regain	
those	abilities	(Chou	et	al,	2005).	
	
Types	of	stroke	
	 Strokes	can	be	divided	into	two	major	categories.	The	more	common	
types	of	strokes	are	ischemic	strokes.	Ischemia	is	defined	as	a	restriction	of	
blood	supply	to	tissue,	and	ischemic	strokes	occur	when	a	clot	blocks	a	blood	
vessel	in	the	brain.	Ischemic	strokes	account	for	87%	of	all	strokes	(NSA	2016).	
Ischemic	strokes	can	be	further	subdivided	into	two	subcategories,	based	on	
where	the	clot	originates.	In	an	embolic	ischemic	stroke,	the	blood	clot	forms	in	
another	part	of	the	body	other	than	the	brain	(typically	the	heart).	The	clot	then	
travels	through	the	circulatory	system	until	it	reaches	the	brain,	where	it	
proceeds	to	obstruct	a	blood	vessel	with	a	diameter	small	enough	to	catch	it	
(NSA	2016).	The	second	class	of	ischemic	strokes	are	thrombotic	ischemic	
strokes.	In	thrombotic	ischemic	strokes,	a	clot	forms	within	a	blood	vessel	in	the	
brain.	The	clot	will	steadily	grow	in	size	until	it	blocks	the	artery	(NSA	2016).	
	 The	second	type	of	strokes	are	hemorrhagic	strokes.	A	hemorrhage	is	
defined	as	a	loss	of	blood	from	a	ruptured	blood	vessel.	In	a	hemorrhagic	stroke,	
a	blood	vessel	in	the	brain	ruptures	open	and	spills	blood	into	the	surrounding	
brain	tissue.	Although	hemorrhagic	strokes	account	for	only	15%	of	all	strokes,	
they	account	for	40%	of	stroke	fatalities	(NSA	2016).	Hemorrhagic	strokes	can	
further	be	divided	into	two	sub‐categories	based	on	where	they	occur.		An	
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intracerebral	hemorrhage	occurs	when	a	blood	vessel	within	the	brain	tissue	
ruptures.	A	subarachnoid	hemorrhage	occurs	when	a	blood	vessel	that	lies	
between	the	brain	and	a	surrounding	layer	of	tissue	known	as	the	arachnoid	
mater	bursts	and	bleeds	into	the	subarachnoid	space	(NSA	2016).	
	 Sometimes,	individuals	will	suffer	from	stroke‐like	symptoms	for	less	
than	24	hours,	and	then	the	symptoms	will	reside.	These	events	are	known	as	
transient	ischemic	attacks.	Transient	ischemic	attacks	occur	when	blood	flow	to	
the	brain	is	temporarily	halted.	Although	transient	ischemic	attacks	do	not	cause	
the	death	of	brain	tissue,	they	can	be	a	harbinger	of	future	strokes	and	warrant	
medical	attention	(NSA	2016).		
	
Current	Pharmacological	Treatments	for	Ischemic	Strokes	
	 The	only	agent	that	is	used	to	treat	strokes	in	an	immediate	setting	is	
tissue	plasminogen	activator	(Mayo	Clinic	2016).	Tissue	plasminogen	activator	is	
an	enzyme	that	is	found	on	endothelial	cells	that	line	the	inside	of	blood	vessels.	
It	is	responsible	for	converting	the	inactive	enzyme	plasminogen	into	the	active	
enzyme	plasmin.	Plasmin	is	the	major	enzyme	responsible	for	the	breakdown	of	
clots	(The	National	Institute	of	Neurological	Disorders	and	Stroke	rT‐PA	Stroke	
Study	Group	2015).	Because	of	its	mechanism	of	action,	tissue	plasminogen	
activator	is	only	used	to	treat	ischemic	strokes,	not	hemorrhagic	strokes.	Tissue	
plasminogen	activator	is	administered	intravenously,	and	must	be	administered	
within	3‐4.5	hours	of	the	onset	of	stroke	symptoms.		As	tissue	plasminogen	
activator	is	administered,	it	will	dissolve	the	ischemic	clot	in	an	individual’s	
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brain,	restoring	blood	flow	to	the	affected	area.	Because	time	is	of	the	essence	
concerning	ischemia,	the	faster	the	clot	is	removed,	the	less	the	damage	there	
will	be	(Mayo	Clinic	2016).		
	 The	use	of	this	agent	is	not	without	risks.	Tissue	plasminogen	activator	
has	numerous	potential	side	effects,	most	notably,	the	ability	to	cause	
hemorrhagic	bleeding	within	the	brain.	In	order	to	prevent	this	from	happening,	
a	litany	of	criteria	have	been	developed	to	help	medical	providers	assess	
whether	or	not	their	patient’s	qualify	for	the	agent.		In	addition	to	being	outside	
of	the	aforementioned	time	window,	patients	will	be	excluded	from	
administration	if	they	have	evidence	of	active	cranial	bleeding,	a	history	of	
cranial	bleeding,	or	a	suspicion	of	cranial	bleeding.	Furthermore,	patients	will	be	
excluded	for	uncontrolled	hypertension,	a	witnessed	seizure	at	stroke	onset,	
acute	bleeding	tendencies,	current	treatment	with	anti‐coagulation	medication,	
head	or	neck	surgery	within	the	past	3	months,	head	trauma	within	the	last	
three	months,	evidence	of	a	tumor	or	aneurysm	or	a	positive	pregnancy	test	(del	
Zoppo	et	al,	1992).		By	employing	these	strict	criteria,	health	care	providers	can	
effectively	limit	the	risk	of	an	intracranial	bleed.		
	 Another	pharmacologic	agent	that	is	employed	in	the	immediate	presence	
of	an	ischemic	stroke	is	aspirin.	Aspirin	is	defined	as	a	non‐steroidal	anti‐
inflammatory	drug.	Its	two	primary	mechanisms	of	action	are	decreasing	
inflammation	and	thinning	the	blood.	Aspirin	does	not	have	any	direct	effect	on	a	
stroke	in	progress.	Instead,	it	is	used	to	reduce	the	likelihood	of	having	another	
ischemic	stroke	in	the	immediate	(Mayo	Clinic	2016).		The	therapeutic	effects	of	
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aspirin	in	this	regard	are	primarily	achieved	by	inhibiting	the	enzyme	
cyclooxygenase‐1	(Bellavance	1993).	The	importance	of	inhibiting	
cyclooxygenase‐1	relates	to	its	function	in	the	arachidonic	acid	pathway.		
Arachidonic	acid	is	a	polyunsaturated	omega‐6	fatty	acid	that	is	found	
predominantly	in	the	phospholipid	cellular	membranes.	Arachidonic	acid	is	used	
as	a	lipid	second	messenger	within	the	membrane,	and	can	be	released	from	the	
membrane	by	the	enzyme	phospholipase‐A2	(Bellavance	1993).	Once	released,	
cyclooxygenase‐1	converts	arachidonic	acid	into	prostaglandin‐H2,	which	is	then	
converted	into	thromboxane	by	the	enzyme	thromboxane	synthase.	
Thromboxane	is	a	lipid	that	is	integral	in	the	binding	of	platelets	to	create	clots	
(Bellavance	1993).	By	inhibiting	cyclooxygenase‐1,	aspirin	prevents	the	creation	
of	prostaglandin‐H2,	and	thereby	prevents	the	creation	of	thromboxane.	Without	
presence	of	thromboxane,	platelets	are	far	less	likely	to	aggregate	and	form	clots,	
thereby	reducing	the	risk	of	a	secondary	ischemic	stroke.		
	
Post‐stroke	disabilities	and	rehabilitation		
	 The	damage	caused	to	neural	tissue	by	a	stroke	is	often	severe,	and	the	
ability	for	neural	tissue	to	regenerate	is	limited.	In	order	to	regain	some	
semblance	of	function	in	a	post‐stroke	patient,	aggressive	physical	rehabilitation	
is	often	employed.	Post‐stroke	rehabilitation	allows	individuals	who	have	
suffered	from	a	stroke	to	regain	functionality	to	a	point	in	which	they	are	able	to	
function	in	society.	In	some	instances,	post‐stroke	rehabilitation	can	teach	
patients	to	regain	abilities	that	were	once	lost	(how	to	coordinate	one’s	legs	
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when	walking,	for	example).	In	other	cases,	rehabilitation	may	also	teach	
individuals	how	to	circumvent	disabilities	that	are	permanent	(learning	how	to	
bathe	with	one	hand,	learning	to	use	non‐verbal	communication,	etc.)	(National	
Institute	of	Neurological	Disorders	and	Stroke	(NINDS),	2014).	
	 Post‐stroke	rehabilitation	is	typically	employed	once	a	patient	has	
become	medically	stable	(medical	stability	is	generally	defined	as	the	ability	to	
survive	without	immediate	medical	intervention).	The	majority	of	strokes	will	in	
some	way	compromise	the	motor	function	of	an	individual.	Initial	rehabilitation	
encourages	individuals	to	attempt	as	much	individual	movement	as	possible	
(NINDS,	2014).	Physical	therapists	will	often	employ	passive	and	active	
movement	exercises	in	order	to	strengthen	affected	limbs.	Passive	exercises	
involve	assistance	in	moving	an	affected	limb,	while	active	exercises	require	the	
individual	to	move	the	affected	limb	without	assistance.	Patients	may	then	
progress	to	sitting,	standing	and	walking	with	and	without	assistance.	Once	
some	form	of	mobility	has	been	obtained,	therapy	then	advances	to	more	
complex	tasks	such	as	eating,	bathing,	dressing	and	toileting	(NINDS	2014).	
	 In	addition	to	mobility	disabilities,	there	are	litanies	of	other	disabilities	
that	can	arise	from	a	stroke,	depending	on	what	areas	of	the	brain	are	damaged.	
Individuals	may	have	disturbances	in	sensory	perception.	They	may	be	unable	to	
differentiate	temperature,	pain	or	position	of	affected	areas	of	the	body.	
Individuals	may	feel	un‐stimulated	tingling	sensations	(known	as	paresthesias),	
or	they	may	experience	painful	sensations	from	nerve	damage	(Kim	2014).	One	
in	four	stroke	victims	will	have	aphasia,	which	is	defined	as	an	inability	for	an	
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individual	to	properly	communicate	(NINDS	2014).	The	dominant	language	
processing	centers	are	often	located	in	the	left	hemisphere	of	the	brain.	In	the	
posterior	left	hemisphere	of	the	brain	sits	Wernicke’s	area.	Wernicke’s	area	is	
responsible	for	interpreting	received	communication.	If	damaged,	individuals	
will	lose	the	ability	to	interpret	spoken	or	written	language.	They	are	able	to	
produce	grammatically	correct	sentences,	but	these	sentences	will	often	be	
incoherent	and	devoid	of	meaning	(Plowman	et	al,	2012).		This	disability	is	
known	as	receptive	aphasia.	In	the	anterior	part	of	the	left	hemisphere	lies	
Broca’s	area.	Individuals	with	damage	to	Broca’s	area	can	understand	
communication,	but	lose	the	ability	to	express	their	thoughts	through	spoken	or	
written	words.	This	is	known	as	expressive	aphasia.		Significant	damage	to	the	
brain	can	lead	to	global	aphasia,	where	individuals	can	neither	understand	nor	
express	communication	(Plowman	et	al,	2012).	Finally,	stroke	patients	can	suffer	
from	disabilities	in	thinking	and	memory.	Individuals	may	not	be	able	to	
acknowledge	their	disabilities	(referred	to	as	anosognosia),	or	may	not	be	able	
to	respond	to	stimuli	originating	from	the	area	of	the	body	that	is	afflicted	by	the	
stroke	(referred	to	as	neglect)	(Kauhanen	et	al,	2000).	There	is	also	a	condition	
in	which	individuals	cannot	carry	out	planned	motor	tasks	when	asked,	despite	
an	understanding	of	the	request	and	willingness	to	perform	the	task.	This	
condition	is	known	as	apraxia	(Kauhanen	et	al,	2000).		
	
	
	
	 8
Post‐stroke	Neurogenesis	
	 Neurogenesis	is	the	process	by	which	new	nerve	cells	are	generated	from	
stem	and	progenitor	cells.		In	adults,	there	are	two	zones	within	the	human	brain	
that	have	been	identified	as	zones	of	perpetual	neurogenesis.	They	are	the	
subgranular	zone	(which	is	part	of	the	dentate	gyrus	of	the	hippocampus)	and	
the	subventricular	zone	(Dayer	et	al,	2003;	Ernst	et	al,	2014).	Most	strokes	do	
not	occur	within	the	hippocampal	region;	therefore,	when	concerning	post	
stroke	neurogenesis,	the	subventricular	zone	is	of	greater	interest	(Carmichael	
2015).		When	brain	tissue	is	damaged,	stem	cell	populations	begin	to	divide	and	
send	immature	neurons	to	the	site	of	damage.	The	subventricular	zone	contains	
three	different	types	of	cell	populations.	First,	there	are	the	immature	neuroblast	
cells.		Further	down	the	development	line	are	multipotent	neural	progenitor	
cells	that	can	produce	astrocytes,	oligodendrocytes	and	neurons.	Finally,	there	
are	rapidly	dividing	cells	that	more	closely	resemble	the	final	cell	lineage	of	an	
adult	brain.	(Carmichael	2015).	These	cell	lines	migrate	to	the	regions	of	damage	
(known	as	the	peri‐infarct	regions)	and	cluster	around	angiogenic	blood	vessels	
within	the	cortical	tissue	adjacent	to	the	damaged	areas.	These	combined	
neurovascular	areas	are	typical	of	post‐stroke	neurogenesis	(Carmichael	2015).	
	 There	are	numerous	cytokine	and	chemokine	pathways	that	guide	
neuronal	migration	from	the	subventricular	zone	to	the	site	of	the	stroke.	
Although	endogenous	erythropoietin	is	typically	linked	to	angiogenesis,	it	has	
also	been	shown	to	be	induced	by	strokes	and	encourage	neuroblast	migration	
(Tsai	et	al,	2006).	Both	stromal	derived	factor‐1	and	angiopoeitin‐1	are	induced	
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by	peri‐infarct	blood	vessels	and	serve	as	a	tropic	signal	for	migrating	
neuroblasts	to	the	damaged	regions	of	the	brain	(Ohab	et	al,	2006).		
	
STROKE	RESEARCH	
	 The	burden	of	strokes	on	society	is	tremendous.	A	stroke	occurs	every	40	
seconds	in	the	United	States,	and	every	four	minutes,	an	American	dies	from	a	
stroke	(NSA	2016).	Much	of	the	current	pharmacologic	treatments	concerning	
strokes	are	preventative,	and	there	is	a	dearth	of	treatments	available	for	
individuals	who	have	suffered	an	acute	ischemic	stroke.	Much	of	the	current	
research	being	done	involves	discovering	effective	treatments	for	post‐stroke	
individuals.		
	
Animal	model	
	 Currently,	the	most	common	models	to	test	the	efficacy	of	post‐stroke	
pharmacologic	agents	are	animal	models.	When	concerning	a	suitable	animal	
model,	there	are	several	factors	to	be	considered.	The	closer	an	animal	
resembles	a	human	physiologically,	the	more	ideal	candidate	it	becomes.	
Expense,	practicality	and	the	available	resources	of	the	lab	also	need	to	be	taken	
into	account.	Currently,	the	two	most	common	taxonomic	orders	that	are	used	
are	the	Lagomorpha	(primarily	consisting	of	hares	and	rabbits)	and	the	Rodentia	
(which	include	mice,	rats	and	squirrels,	amongst	others)	(Casals	et	al,	2011).		
	 Within	a	laboratory	setting,	extraneous	variables	are	tightly	controlled.	
This	is	done	to	ensure	that	there	are	no	confounding	factors	that	may	skew	the	
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data	in	one	direction	or	another.	This	can	be	problematic,	however,	when	
attempting	to	translate	experimental	results	into	practical	use.	Animal	subjects	
tend	to	be	younger	and	free	of	chronic	illnesses.	Such	a	population	of	subjects	
would	not	be	representative	of	the	American	population.	Many	individuals	who	
suffer	from	strokes	also	suffer	from	concomitant	chronic	illnesses	such	as	
diabetes,	emphysema,	or	heart	failure.	Some	of	these	illnesses	increase	the	
likelihood	of	a	suffering	a	stroke,	while	others	may	compromise	an	individual’s	
ability	to	heal	(Casals	et	al,	2011).			
Furthermore,	age	is	the	primary	risk	factor	for	strokes,	so	employing	
younger	animal	subjects	may	not	produce	data	that	is	applicable	to	the	human	
population	(Casals	et	al,	2011).	In	an	attempt	to	more	accurately	simulate	a	real‐
world	stroke	situation,	our	lab	employs	older	rats	(Corbett	et	al,	2015).		Rats	are	
suitable	subjects	due	to	the	fact	that	their	cerebral	vasculature	is	similar	to	that	
of	higher	mammalian	organisms	(Durukan	et	al,	2009).	Furthermore,	previous	
trials	have	indicated	that	when	both	young	and	old	rats	have	an	induced	
ischemic	stroke,	there	are	differences	in	the	outcomes,	including	the	total	
volume	of	affected	tissue,	post‐stroke	edema	and	functional	disabilities	(Joutel	et	
al,	2010).	This	indicates	that	there	are	appreciable	differences	in	the	brains	of	
younger	and	older	rats.		Our	lab	conducted	parallel	trials	with	both	male	and	
female	rats	in	order	to	account	for	any	differences	between	the	two	genders.		
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Induction	models	
	 There	are	multiple	models	available	when	trying	to	induce	an	ischemic	
stroke	in	animal	subjects.	The	type	of	model	that	a	lab	employs	is	dependent	on	
multiple	factors,	including	cost,	ease	of	use	and	available	resources.	The	most	
common	methodology	of	stroke	induction	involves	physical	occlusion	of	the	
middle	cerebral	artery	using	surgical	ligation	(Rossmeisl	et	al,	2007).	The	middle	
cerebral	artery	is	present	in	both	humans	and	rats.	In	the	human	population,	the	
middle	cerebral	artery	is	the	largest	of	the	cerebral	arteries,	and	it	is	the	most	
commonly	affected	artery	in	a	cerebrovascular	accident	(Slater	2015).		The	
damage	caused	by	occluding	the	middle	cerebral	artery	in	animal	models	has	
been	shown	to	mimic	the	damage	caused	by	middle	cerebral	artery	ischemic	
strokes	in	adult	humans	(Casals	et	al	2011).	Occluding	the	middle	cerebral	artery	
induces	an	ischemic	infarct	that	is	limited	to	the	cortex	of	the	brain.	The	cortex	is	
the	outer	“gray	matter”	of	the	cerebrum,	where	much	of	the	synapses	and	cell	
bodies	of	the	brain	lie.	The	“white	matter”,	in	comparison,	is	primarily	composed	
of	myelinated	nerve	tracts	that	carry	information	signals.	The	white	matter	
tracts,	as	well	as	the	internal	structures	of	the	brain	(hippocampus,	basal	ganglia,	
etc.)	are	not	affected	by	a	middle	cerebral	artery	ischemic	stroke	(Chen	et	al,	
1986).	
There	are	other	methodologies	of	inducing	a	middle	cerebral	artery	
stroke	that	do	not	involve	physically	occluding	the	artery.	Endothelin‐1	is	a	
powerful	vasoconstrictive	protein	that	can	be	injected	at	precise	points	within	
the	animal	cerebrum.	Endothelin‐1	will	cause	microvessels	to	constrict,	leading	
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to	ischemic	lesions	within	the	brain.	By	injecting	endothelin‐1	into	the	area	of	
the	brain	that	is	supplied	by	the	middle	cerebral	artery,	a	middle	cerebral	artery	
ischemic	stroke	can	be	replicated	(Casals	et	al,	2011).		
Middle	cerebral	artery	strokes	can	also	be	replicated	by	introducing	
synthetic	emboli.	Microbeads,	synthetic	rubber	cylinders	and	preformed	platelet	
clots	can	be	injected	into	the	internal	carotid	artery,	which	eventually	feeds	into	
the	middle	cerebral	artery.	The	drawback	to	this	methodology	is	the	lack	of	
control	over	the	location	of	the	infarcts.	Infarcts	can	occur	in	the	cortex,	basal	
ganglia	and	caudate	nucleus	(Bailey	et	al,	2009).	
In	addition	to	middle	cerebral	artery	strokes,	there	are	other	
methodologies	available	to	target	various	regions	within	the	brain.	Perforating	a	
pial	artery	on	the	surface	of	the	brain	using	forceps	or	photochemical	irradiation	
will	occlude	arteries	that	supply	the	internal	structures	of	the	brain.	These	
arteries	are	known	as	the	lenticulostriate	arteries,	and	the	occlusion	occurs	by	
an	eosinophilic	thrombus.	Infarcts	to	the	brain’s	internal	structures	are	known	
as	lacunar	infarcts	(Pevsner	et	al,	2001;	Hua	et	al,	2006).	
For	the	purposes	of	our	experiments,	our	lab	employed	the	endothelin	
model	for	stroke	induction	(Corbett	et	al,	2015).	By	employing	endothelin‐1,	we	
are	able	to	induce	a	localized	ischemic	infarct	within	our	animal	subjects.	
Endothelin‐1	is	also	relatively	stable,	easy	to	use,	and	has	consistently	provided	
repeatable	study	results.		
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PHARMOCOGLIC	TREATMENT	
	 There	are	multiple	variables	concerning	post‐stroke	pharmacologic	
treatment.	Identifying	a	particular	drug	is	only	one	aspect	of	the	equation.	The	
dosage	of	the	drug,	the	timing	of	its	application,	and	the	side‐effect	profile	must	
all	be	taken	into	consideration.		
	 Currently,	our	lab	is	testing	the	post‐stroke	effects	of	three	pharmacologic	
agents.	Those	agents	are	fluoxetine,	ascorbic	acid	(vitamin	C)	and	simvastatin.	
Our	lab	is	testing	multiple	different	possible	regimens.	In	addition	to	each	drug	
being	tested	separately,	drugs	are	tested	in	combination,	tested	along	with	
rehabilitation,	and	tested	on	both	male	and	female	rats.		
	
Selective	Serotonin	Reuptake	Inhibitors		
	 Fluoxetine	is	part	of	a	class	of	pharmacological	agents	known	as	selective	
serotonin	reuptake	inhibitors	(SSRIs)	(de	Jonghe	et	al,	1997).	The	primary	site	of	
action	for	these	pharmacologic	agents	is	at	the	synaptic	junction	of	nerve	cells	
within	the	brain.	Pre‐synaptic	cells	will	release	the	neurotransmitter	serotonin	
onto	post‐synaptic	cells	in	the	brain.	Serotonin	will	bind	onto	specific	receptor	
sites	on	the	post‐synaptic	membrane.	After	binding,	serotonin	will	release	from	
the	post‐synaptic	receptors	and	go	back	into	the	pre‐synaptic	cells.	The	primary	
mechanism	of	action	for	SSRIs	is	to	inhibit	the	re‐uptake	of	serotonin	by	the	pre‐
synaptic	cells.	This	allows	serotonin	to	have	prolonged	contact	with	the	post‐
synaptic	receptors	(de	Jonghe	et	al,	1997).		
	 14
	 SSRIs	are	primarily	employed	in	the	treatment	of	clinical	depression	(de	
Jonghe	et	al,	1997).	Their	use	within	psychiatric	medicine	has	been	expanded	to	
generalized	anxiety	disorders,	obsessive‐compulsive	disorder,	panic	disorder,	
phobias,	bulimia	and	post‐traumatic	stress	disorder.	In	addition,	SSRIs	are	
employed	for	the	prophylactic	treatment	of	migraines,	nerve	pain	caused	by	
diabetes,	premature	ejaculation	and	fainting	spells	(Stone	et	al,	2003).		
	 SSRIs	have	been	investigated	in	post‐stroke	patients	for	a	number	of	
years.	The	initial	investigations	tested	the	ability	of	SSRIs	to	treat	individuals	
who	were	suffering	from	depressive	symptoms	in	a	post‐stroke	environment.	
Studies	have	posited	a	hypothesis	that	one	of	the	causes	of	clinical	depression	is	
the	degeneration	of	central	nervous	tissue,	and	have	noted	the	neuro‐
regenerative	capabilities	of	SSRIs	(Samuels	et	al,	2011;	David	et	al,	2009;	Rayen	
et	al,	2011).		
	
Fluoxetine	
	 Fluoxetine,	also	known	as	by	its	trade	name	Prozac,	is	the	oldest	SSRI.	It	
was	first	synthesized	in	1972,	and	was	approved	by	the	United	States	Food	and	
Drug	Administration	in	1987	(Wong	et	al,	1995).	As	one	of	the	most	commonly	
prescribed	SSRIs,	it	is	frequently	used	in	clinical	trials	and	experiments.	
Fluoxetine	has	been	shown	to	improve	the	rehabilitation	outcomes	of	patients	
who	have	suffered	strokes	and	incurred	motor	disabilities.	Patients	who	suffered	
from	hemiplegia	(paralysis	localized	to	one	half	of	the	body)	showed	
improvement	in	walking	and	activities	of	daily	living	when	placed	on	a	post	
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stroke	course	of	fluoxetine	(Dam	et	al,	1996).	In	a	clinical	trial	known	as	the	
FLAME	(FLuoxetine	for	Motor	rEcovery	after	ischemic	stroke)	trial,	humans	who	
suffered	from	moderate	and	severe	motor	difficulties	also	showed	significant	
improvement	after	a	three‐month	regimen	of	fluoxetine	post	stroke	(Chollet	et	
al,	2011).	Improvement	in	motor	function	was	shown	to	be	independent	of	the	
administration	of	clot‐busting	pharmacologic	agents,	improvement	of	depressive	
symptoms,	or	other	confounding	factors	(Chollet	et	al,	2011).			
	 There	are	multiple	proposed	mechanisms	as	to	why	fluoxetine	helps	
improve	functional	outcomes	in	patients	who	have	disabilities	due	to	strokes.	
One	of	the	noted	properties	of	fluoxetine	is	its	ability	to	limit	inflammation	in	a	
post‐ischemic	brain.	Acute	neuronal	damage	caused	by	the	initial	ischemic	event	
is	followed	by	secondary	delayed	neuronal	death	(Lipton	1999;	Kirino	2000).	
The	cause	of	this	delayed	injury	is	attributed	to	post‐ischemic	inflammation	
(Zheng	et	al,	2004).	High	dose	administration	of	fluoxetine	suppressed	the	
infiltration	of	microglial	cells	and	neutrophils	into	the	infarct	area	and	
suppressed	the	ability	for	these	cells	to	release	pro‐inflammatory	cytokines	in	a	
post‐stroke	infarct	in	rats	(Lim	et	al,	2008).	Fluoxetine	has	also	been	shown	to	
activate	the	pituitary‐adrenocortical	axis	in	rats	by	potentiating	serotonergic	
receptors	in	the	brain.	Activating	this	endocrine	axis	leads	to	the	eventual	
release	of	cortisol	from	the	adrenal	glands;	cortisol	serves	as	anti‐inflammatory	
hormone	(Bianchi	et	al,	1994).		
In	addition	to	suppressing	damage	caused	by	inflammation,	fluoxetine	
has	also	been	shown	to	help	prevent	oxidative	damage	caused	by	free	radicals.	
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Chronic	administration	of	fluoxetine	over	a	21‐day	period	significantly	enhances	
production	of	endogenous	antioxidants	such	as	superoxide	oxidoreductase	in	
rats	(Zafir	et	al,	2007).	Endogenous	antioxidants	limit	damage	caused	by	
oxidative	stress	by	binding	to	reactive	oxygen	species	such	as	hydrogen	
peroxide.	Fluoxetine	administration	also	improved	the	viability	of	a	neuroblastic	
cell	line	in	rats	known	as	PC12	by	increasing	the	activity	of	superoxide	
dismutase,	one	of	the	most	important	antioxidants	in	the	body	(Kolla	et	al,	
2005).		
Fluoxetine	has	also	been	shown	to	help	improve	neuroplasticity	by	
increasing	uptake	of	various	protein	growth	factors.	Brain‐derived	neurotrophic	
factor	(BDNF)	is	one	of	the	fundamental	growth	proteins	in	the	human	brain.	In	
the	mature	adult	brain,	BDNF	promotes	elaboration	and	refinement	of	the	neural	
circuit	structure,	modulates	synaptic	activity	and	regulates	cognitive	brain	
function.		By	modulating	the	complexity	and	density	of	dendritic	spines,	BDNF	is	
one	of	the	primary	factors	for	central	nervous	system	plasticity	(Anastasia	et	al,	
2014).		Fluoxetine	has	been	shown	to	up‐regulate	cyclic	adenosine	
monophosphate	(cAMP)	response	element	binding	protein	(CREB)	in	rats.	CREB	
is	a	transcription	factor	that	is	responsible	for	transcribing	the	gene	that	codes	
for	BNDF.	By	up‐regulating	CREB,	fluoxetine	can	increase	BNDF	expression	and	
help	promote	neuroplasticity	in	a	post‐ischemic	infarct	environment	(Nibuya	et	
al,	1996;	Coppell	et	al,	2003).	Fluoxetine	has	also	been	shown	to	improve	spatial‐
cognitive	reasoning	in	rats	by	increasing	neurogenesis	in	hippocampal	regions	
that	have	been	damaged	by	ischemia	(Li	et	al,	2009).		
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Another	hypothesis	is	that	serotonin	is	one	of	the	key	neurotransmitters	
involved	in	motor	output,	and	by	increasing	serotonin	binding	in	the	synaptic	
cleft	of	central	nerve	cells,	motor	output	that	has	been	compromised	by	an	
ischemic	infarct	can	be	improved	upon.		Primary	serotonergic	neurons	in	the	
pontine‐mesocephalic	and	medullary	areas	are	responsible	for	tonic	motor	
activity,	and	a	subset	of	serotonergic	neurons,	when	over‐activated,	results	in	
rapid	motor	movements	(Jacobs	et	al,	1997).	Functional	magnetic	resonance	
imaging	of	humans	confirms	that	fluoxetine	over‐activates	the	motor	cortices	in	
the	human	brain	compared	with	placebos	(Chollet	et	al,	2011).	
Finally,	serotonin	is	a	known	platelet	agonist.	Platelets	are	one	of	the	
primary	blood	components	involved	in	the	clotting	cascade.	Serotonin	works	by	
enhancing	platelet	aggregation	induced	by	adenosine	diphosphate	(ADP).	
Serotonin	also	works	in	conjunction	with	thrombin	to	increase	the	activity	of	the	
clotting	cascade	(Li	et	al,	1997).	By	prolonging	serotonergic	action	in	the	
synaptic	cleft,	it	is	possible	that	the	activity	of	the	clotting	cascade	is	increased	
and	the	potential	of	a	post‐ischemic	bleed	is	reduced.	Post‐ischemic	bleeding	is	a	
negative	outcome,	as	it	further	reduces	the	amount	of	blood	that	brain	tissue	
receives.	By	limiting	the	potential	for	a	bleed,	the	number	of	pathologic	
manifestations	from	the	original	ischemic	insult	can	be	minimized.			
	
Statins	
	 The	drug	simvastatin	is	part	of	a	class	of	drugs	known	as	statins.	Statins’	
primary	method	of	action	involves	competitively	inhibiting	the	enzyme	3‐
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hydroxy‐3‐methyl‐glutaryl	coenzyme‐A	(HMG	CoA)	reductase	(Baigent	et	al,	
2005).	HMG	CoA	reductase	is	the	rate‐controlling	enzyme	in	the	mevalonate	
pathway	(Goldstein	et	al,	1990).	The	mevalonate	pathway	is	an	essential	
metabolic	pathway,	and	it	is	also	the	primary	biochemical	pathway	responsible	
for	the	synthesis	of	cholesterol.	The	mevalonate	pathway	starts	with	the	
molecule	acetyl	coenzyme‐A	(acetyl‐coA).	Acetyl‐coA	is	the	end	product	of	
multiple	biochemical	processes,	including	the	metabolism	of	amino	acids,	the	
degradation	of	fatty	acids	and	the	metabolism	of	glucose	(Goldstein	et	al,	1990).	
Acetyl‐coA	enters	the	mevalonate	pathway	and	is	eventually	converted	into	
isopentenyl	pyrophosphate	and	dimethyallyl	pyrophosphate.	These	two	
molecules	are	five‐carbon	building	blocks	for	the	isoprenoids.	Isoprenoids	are	a	
diverse	class	of	biomolecules	that	includes	cholesterol.		
	 At	the	cellular	level,	cholesterol	is	an	important	component	of	the	cellular	
membrane.	The	cellular	membrane	is	a	lipid	bilayer,	which	can	transition	from	
solid	(gel)	phase	to	liquid	phase.	When	in	liquid	phase,	the	embedded	proteins	
can	flow	freely	throughout	the	cellular	membrane.	When	cholesterol	is	added	to	
the	lipid	bilayer,	it	disrupts	the	“packing”	architecture	of	the	membrane	and	
increases	the	membrane	fluidity,	allowing	for	greater	mobility	of	the	protein	
components	of	the	membrane.	Cholesterol	also	serves	to	demarcate	the	lipid	
rafts	of	the	cell	membrane.	Lipid	rafts	are	contained	platforms	of	lipids	and	
proteins	that	move	within	the	lipid	bilayer	as	a	unit,	and	serve	to	help	regulate	
membrane	function	(Simons	et	al,	2002).	
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Statins	are	primarily	employed	to	decrease	cholesterol	levels	in	
individuals.	By	inhibiting	HMG	CoA	reductase,	statins	inhibit	the	eventual	
synthesis	of	cholesterol	(Baigent	et	al,	2005).	Because	cholesterol	is	not	soluble	
in	water,	it	must	be	carried	on	proteins	through	the	blood	plasma.	These	
combined	cholesterol‐protein	molecules	are	known	as	lipoproteins.	
Lipoproteins	are	classified	by	their	density:	very	low‐density	lipoproteins	
(VLDL),	low‐density	lipoproteins	(LDL),	intermediate‐density	lipoproteins	(IDL)	
and	high‐density	lipoproteins	(HDL)	(Durrington	2003).	Chronically	elevated	
levels	of	cholesterol	(especially	LDL)	have	been	linked	to	atherosclerosis	(a	
buildup	of	fatty	plaques	within	the	walls	of	arteries)	and	coronary	artery	
disease.	HDL	is	the	exception,	as	it	has	shown	to	be	cardio‐protective.	The	
primary	cause	of	elevated	cholesterol	levels	in	the	general	population	includes	a	
lack	of	physical	activity	and	high‐cholesterol	diets,	but	it	can	also	be	caused	by	
genetic	mutations	in	cholesterol	receptors	or	by	concomitant	illnesses	(such	as	
diabetes	or	an	underactive	thyroid	gland)	(Durrington	2003).		
There	have	been	numerous	studies	attempting	to	investigate	whether	or	
not	statins	have	any	utility	in	treating	post‐stroke	patients.	Studies	have	
investigated	treating	post‐stroke	dementia	in	humans,	increasing	vasodilation	in	
rats	in	a	post‐infarct	area,	exerting	anti‐inflammatory	properties	in	rats	in	
ischemic	strokes	and	decreasing	overall	mortality	in	post‐stroke	humans	
(Ankolekar	et	al,	2010;	Endres	et	al,	2004;	Tan	et	al,	2003;	Elkin	2005).		
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Simvastatin	
	 Simvastatin	first	came	to	market	in	1992,	although	it	is	not	the	first	statin	
that	was	ever	produced.	The	development	of	simvastatin	was	closely	tied	with	
the	development	of	its	precursor,	lovastatin.	Both	of	these	agents	are	
synthesized	from	the	fungus	Aspergillus	terreus.	Simvastatin	was	synthesized	
from	the	by‐products	of	fermenting	Aspergillus	terreus,	and	it	was	shown	to	be	a	
far	more	potent	inhibitor	of	HMG‐coA	reductase	(Li	2009).	By	1994,	simvastatin	
had	unequivocally	been	shown	to	reduce	both	the	total	number	of	documented	
cardiac	events	and	the	mortality	of	cardiac	events	in	humans	with	elevated	
cholesterol	(Pederson	et	al,	1994).		Today,	it	is	listed	on	the	World	Health	
Organizations	List	of	Essential	Medicines,	which	lists	the	most	important	
medications	necessary	for	a	basic	health	system	(World	Health	Organization	
(WHO)	2015).		
	 Because	cholesterol	is	found	in	all	cell	membranes,	statins	have	the	
capability	of	affecting	every	organ	system	in	the	body.	The	primary	mechanism	
of	action	for	simvastatin	is	not	exclusively	localized	to	the	central	nervous	
system.	There	has	been	evidence,	however,	that	simvastatin	has	neuro‐
protective	and	neuro‐regenerative	capabilities.	Rats	with	normal	cholesterol	
levels	that	are	prophylactically	treated	with	statins	show	increased	cerebral	
blood	flow,	reduced	ischemic	infarct	size	and	improved	neurologic	function	post‐
stroke	(Endres	et	al,	1998).	This	neuro‐protective	capability	of	statins	has	been	
hinted	at	in	several	human	clinical	studies	(Marti‐Fabregas	et	al,	2004;	Jonsson	
et	al,	2001).	Even	if	subjects	are	not	being	given	statins	prophylactically,	statins	
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have	been	shown	to	limit	the	damage	of	an	ischemic	stroke	if	given	in	an	
immediate	post‐ischemic	stroke	environment	in	rats	(Sironi	et	al,	2003;	Moonis	
et	al,	2005).		A	meta‐analysis	of	human	statin	trials	indicated	that	individuals	
who	were	being	treated	with	statins	pre‐stroke	or	who	were	treated	with	statins	
during	an	ischemic	infarct	event	had	been	able	to	regain	more	functionality	and	
had	lower	mortality	rates	post‐stroke	(Ni	Chroinin	et	al,	2013).		
The	protective	and	regenerative	capabilities	of	statins	are	attributed	to	
their	ability	to	up‐regulate	nitric	oxide	generated	by	endothelial	nitric	oxide	
synthase	(eNOS).	Nitric	oxide	has	multiple	qualities	that	make	it	ideal	for	
treating	and	protecting	against	ischemic	strokes.	It	is	a	vasodilator,	allowing	for	
increased	cerebral	blood	flow	to	ischemic	areas.		In	addition,	eNOS	possesses	
anti‐inflammatory	and	anti‐thrombotic	properties	(Endres	et	al,	2004;	Vaughan	
et	al,	1999).	A	chronic	pre‐treatment	with	statins	led	to	reduced	biomarkers	
associated	with	platelet	aggregation	in	mice	(Endres	et	al,	1998).	eNOS	also	
facilitates	leukocyte	adhesion	and	increases	the	production	of	the	anti‐oxidant	
enzyme	superoxide	dismutase.		The	presence	of	LDL	has	been	shown	to	
suppress	the	production	of	eNOS	by	acting	through	the	cell	membrane	protein	
caveolin‐1	and	through	LDL	receptor‐1.		In	addition	to	directly	up‐regulating	
eNOS,	statins	can	indirectly	perpetuate	eNOS	activity	by	suppressing	LDL	in	
mice.	(Endres	et	al,	2004).		
In	addition	to	their	global	anti‐cholesterol	properties,	statins	have	shown	
to	have	a	direct	impact	on	neuro‐regeneration	in	post‐ischemic	infarct	
environments.	Low	doses	of	statins	given	one	day	after	a	middle	cerebral	infarct	
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was	induced	in	rats	led	to	the	creation	of	blood	vessels	containing	
bromodeoxyuridine‐reactive	endothelial	cells	(Chen	et	al,	2003).		These	cells	
appeared	in	greater	numbers	compared	to	control	groups.		Bromodeoxyuridine	
is	a	synthetic	nucleoside	that	is	used	to	detect	proliferative	living	tissue.	Its	
presence	in	a	post‐infarct	environment	is	indicative	of	active	angiogenesis.	Post‐
stroke	statins	also	induced	increased	amounts	vascular‐endothelial	growth	
factor	in	the	boundaries	of	the	infarct	area;	vascular‐endothelial	growth	factor	is	
one	of	the	primary	growth	factors	for	angiogenesis	(Chen	et	al,	2003).		
Bromodeoxyuridine	was	also	found	in	increased	amounts	in	the	dentate	gyrus	
and	the	subventricular	zones	(the	two	zones	responsible	for	adult	nerve	cell	
proliferation)	in	post‐ischemic	stroke	rats	(Chen	et	al,	2003).			
Statins	are	also	able	to	promote	vasculogenesis	through	the	Notch	
signaling	pathway.	The	Notch	signaling	pathway	plays	a	major	role	in	the	
regulation	of	embryonic	development	(Zacharek	et	al,	2009).	In	another	
experiment,	simvastatin	was	provided	to	rats	for	seven	days	after	the	induction	
of	an	ischemic	stroke.	Analysis	of	the	brain	tissue	indicated	an	increase	in	Notch	
expression	at	the	border	of	the	ischemic	stroke,	along	with	an	increase	in	
vasculogenesis.		Furthermore,	when	cerebral	arterial	cells	from	these	rats	were	
cultured	with	γ40	secretase	inhibitor	II		(a	protein	that	blocks	Notch	signaling),	
they	showed	a	significant	decrease	in	arterial	migration	when	treated	with	
simvastatin,	compared	to	arterial	cells	that	were	not	cultured	with	the	blocking	
protein	(Zacharek	et	al,	2009).	These	findings	suggest	a	critical	link	between	the	
Notch	signaling	pathway	and	vasculogenesis	in	an	ischemic	infarct	environment.		
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Lastly,	rats	provided	with	post‐stroke	statins	showed	a	significant	
increase	in	the	expression	of	synaptophysin	(Chen	et	al,	2003).		Synaptophysin	is	
a	protein	biomarker	for	pre‐synaptic	plasticity	and	synaptogenesis	(Ujike	et	al,	
2006).	This	combination	of	angiogenesis,	neurogenesis	and	synaptogenesis	
provides	a	biological	base	for	the	improved	outcomes	seen	in	post‐ischemic	
stroke	individuals	who	are	placed	on	a	statin	regimen.		
	
Ascorbic	acid	and	Vitamin	C	
	 Ascorbic	acid	is	an	organic	compound	derived	from	glucose.	The	anion	
form	of	ascorbic	acid	is	known	as	vitamin	C.	Vitamin	C	is	an	essential	nutrient	for	
humans	and	various	other	animal	species;	essential	nutrients	are	nutrients	that	
must	be	ingested	and	can	not	be	produced	by	an	organism	naturally.	Other	
organisms	are	capable	of	producing	vitamin	C	internally	(Lachapelle	et	al,	2010).	
The	fundamental	biological	role	for	vitamin	C	is	that	it	acts	as	a	reducing	agent,	
readily	donating	its	electrons	to	various	enzymatic	reactions.	This	reducing	
capability	also	makes	vitamin	C	a	powerful	antioxidant,	as	it	readily	donates	
electrons	to	neutralize	reactive	oxygen	species	(reactive	oxygen	species	are	
chemically	reactive	molecules	that	can	damage	cells	if	they	accumulate	in	great	
numbers)	(Meister	1994).		
	 One	of	the	most	important	specific	functions	of	vitamin	C	in	mammals	is	
its	place	as	a	common	enzymatic	cofactor	in	the	formation	of	collagen.	Collagen	
is	the	main	structural	protein	in	the	extracellular	space,	and	it	is	the	primary	
component	of	connective	tissue	(tendons,	ligaments,	skin,	etc.)	in	the	
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mammalian	body.	It	is	the	most	abundant	protein	in	the	mammalian	body,	
accounting	for	25%‐35%	of	all	proteins	(Di	Lullo	et	al,	2002).		During	synthesis,	
a	collagen	pre‐cursor,	procollagen,	is	modified	by	the	addition	of	hydroxyl	
groups.	The	hydroxylase	enzymes	that	add	these	groups	require	vitamin	C	as	a	
co‐factor.	These	groups	are	necessary	for	the	later	glycosylation	of	collagen	and	
the	formation	of	collagen’s	triple	helix	structure	(Fratzl	2008).	Without	vitamin	
C,	the	integrity	of	the	collage	triple	helix	is	compromised,	and	resultant	
connective	tissue	lacks	the	strength	to	provide	proper	support.	A	lack	of	vitamin	
C	in	mammals	expresses	itself	as	the	disease	scurvy.	In	scurvy,	organisms	will	
present	with	outward	manifestations	of	connective	tissue	failure.	The	skin	and	
gingiva	will	become	soft	and	spongy.	Because	collagen	provides	structure	to	the	
walls	of	blood	vessels,	individuals	will	start	bruising	easily.	As	the	disease	
progresses,	teeth	will	no	longer	be	stable	in	their	sockets,	and	mucous	
membranes	will	bleed	spontaneously.	Wounds	will	heal	poorly,	placing	the	
individual	at	risk	for	infection.	Eventually,	individuals	risk	death	from	
uncontrollable	bleeding	(Goebel	2015).		
	
Vitamin	C	in	Post‐Ischemic	Cerebral	Infarcts	
	 Compared	to	other	pharmacologic	agents,	there	is	a	paucity	of	viable	
research	concerning	the	effectiveness	of	vitamin	C	in	a	post‐ischemic	infarct	
environment.	The	potential	effectiveness	of	vitamin	C	is	based	on	its	known	
biologic	properties;	its	role	as	an	essential	nutrient,	its	anti‐oxidant	capabilities,	
and	its	necessity	for	the	synthesis	of	the	primary	structural	protein	in	the	body.	
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There	is	some	circumstantial	evidence	that	hints	at	the	potential	utility	of	
vitamin	C	in	post‐stroke	individuals.	When	compared	with	control	groups,	
humans	who	had	suffered	from	ischemic	strokes	had	depleted	blood	levels	of	
vitamin	C	(Sanchez‐Moreno	et	al,	2004).		Although	vitamin	C	itself	cannot	cross	
the	blood‐brain	barrier,	its	oxidized	form,	dehydroascorbic	acid,	does	cross	the	
blood‐brain	barrier.	When	dehydroascorbic	acid	is	administered	in	intravenous	
form	to	mice	who	have	had	induced	middle	cerebral	artery	occlusions,	there	was	
an	increase	in	reperfusion	cerebral	blood	flow,	a	decrease	in	total	infarct	size	
and	an	overall	decrease	in	mortality	(Huang	et	al,	2001).	There	is	a	body	of	data	
indicating	that	humans	who	are	vitamin	C	depleted	are	at	greater	risk	of	dying	
from	an	ischemic	stroke	compared	to	individuals	who	have	normal	levels	of	
vitamin	C	(Gale	et	al,	1995;	Cherubini	et	al,	2000;	Ascherio	et	al,	1999;	Gey	et	al,	
1993).	
	
Searching	for	an	ideal	drug	combination	
	 Our	lab	has	chosen	to	employ	the	aforementioned	pharmacologic	agents	
in	an	attempt	to	see	which	agent	(or	combination	of	said	agents)	can	offer	the	
greatest	benefit	to	individuals	who	have	suffered	a	cerebral	ischemic	infarct	
(Corbett	et	al,	2015).	The	term	“benefit”	can	be	nebulous,	but	for	the	purposes	of	
this	experiment,	we	define	it	as	minimizing	the	amount	of	brain	tissue	damaged	
by	an	induced	ischemic	infarct	and	reducing	the	size	and	frequency	of	
hemorrhagic	transformations.	The	brain	is	a	highly	specialized	organ,	with	each	
section	having	a	distinct	corresponding	function.	Generally,	the	smaller	the	size	
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of	the	cerebral	infarct,	the	fewer	pathological	manifestations	will	have	to	be	
dealt	with,	and	the	overall	quality	of	life	for	the	individual	will	improve.	It	is	
worth	noting,	however,	that	the	location	of	the	infarct	is	also	critical.	A	small	
stroke	in	a	critical	area	of	the	brain	can	potentially	yield	worse	pathological	
manifestations	when	compared	to	larger	strokes	that	occur	in	less	critical	areas	
of	the	brain.		
	 The	standard	starting	dose	of	fluoxetine	for	a	human	adult	is	20	
milligrams	per	day.	For	rats,	the	corresponding	dose	is	2.5	milligrams	per	
kilogram	per	day.		The	recommended	maximum	dose	for	a	human	adult	is	80	
milligrams	per	day.	For	our	experiment,	rats	were	supplied	with	5	milligrams	
per	kilogram	per	day.	This	dose	would	be	the	human	equivalent	of	40	milligrams	
per	day	(Rx	List	2015).		
	 The	standard	starting	dose	of	simvastatin	for	a	human	adult	is	between	
10	milligrams	to	20	milligrams	per	day.	For	rats,	the	corresponding	dose	is	1.0	to	
2.0	milligrams	per	kilogram.	The	maximum	recommended	dose	for	a	human	
adult	is	40	milligrams	per	day.	For	our	experiment,	rats	were	supplied	with	1.0	
milligram	per	kilogram	per	day.	This	dose	correlates	to	10	milligrams	per	day	in	
an	adult	human	(Rx	List	2016).	Furthermore,	for	the	purposes	of	this	
experiment,	all	rats	were	given	this	dosage	of	simvastatin	once	a	day	for	7	days	
before	the	induction	of	an	ischemic	stroke.	The	reason	for	this	is	that	simvastatin	
is	a	chronic	use	medication.	For	the	human	adult	population,	simvastatin	is	
typically	administered	over	significant	time	periods;	patients	commonly	take	
them	for	life.	Many	patients	who	suffer	from	ischemic	strokes	are	on	a	statin	
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medication	at	the	time	of	the	stroke.	By	placing	the	rats	on	a	pre‐stroke	regimen	
of	simvastatin,	we	seek	to	better	simulate	the	experience	of	the	adult	human	
population.		
	 The	standard	over‐the‐counter	vitamin	C	supplement	if	500	milligrams.	
Vitamin	C	is	water	soluble,	and	therefore,	capable	of	being	rapidly	excreted	by	
the	kidneys.	Because	of	this,	it	is	difficult	to	ascertain	an	exact	maximum	dosage	
of	vitamin	C	per	day.	For	the	purposes	of	our	experiment,	the	rats	were	provided	
with	20	milligrams	per	kilogram	of	vitamin	C	per	day.		
	
POST	ISCHEMIC	INFARCT	BLEEDING	
	 Post	ischemic	infarct	bleeding	is	not	an	uncommon	phenomenon.	The	
chances	of	an	individual	who	has	suffered	from	an	ischemic	stroke	to	also	suffer	
a	secondary	bleed	increases	with	age	and	ischemic	infarct	size	(Otaka	et	al,	
1989).	The	phenomenon	of	bleeding	at	the	site	of	the	ischemic	infarct	is	known	
as	a	hemorrhagic	transformation.	One	of	the	posited	theories	as	to	why	
hemorrhagic	transformations	occur	is	that	the	lack	of	glucose	and	oxygen	to	
brain	tissue	leads	to	energy	failure.	This	energy	failure	leads	to	a	cascade	of	
events,	including	adenosine	tri‐phosphate	(ATP)	depletion,	a	decrease	in	
sodium‐potassium	ATPase	activity,	an	increase	in	intracellular	potassium,	a	
release	of	intracellular	glutamate	and	lactic	acidosis.	All	of	these	events	lead	to	a	
destabilization	of	the	blood	brain	barrier	and	an	eventual	bleed	(Khatri	et	al,	
2012).	Furthermore,	reperfusion	injury	has	also	been	associated	with	
hemorrhagic	transformation.	Reperfusion	injury	occurs	when	tissue	is	damaged	
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by	the	return	of	blood	supply	after	a	period	of	ischemia	or	lack	of	oxygen.	The	
proposed	mechanisms	of	how	reperfusion	injury	causes	a	hemorrhagic	
transformation	include	activation	of	endothelial	cells,	inflammatory	responses,	
leukocyte	recruitment	and	the	swelling	of	the	neural	tissue.	Much	like	energy	
failure,	these	reperfusion	injury	mechanisms	all	lead	to	the	destabilization	of	the	
blood‐brain	barrier	(Khatri	et	al,	2012).		
For	the	purposes	of	this	experiment,	the	presence	or	absence	of	
hemorrhagic	transformations	will	be	monitored.	A	similar	previous	experiment	
performed	in	this	lab	did	show	evidence	of	hemorrhagic	transformation	after	
inducing	ischemic	strokes	(Balch	et	al,	2015).	Hemorrhagic	transformations	are	
a	negative	outcome,	and	we	want	to	be	sure	that	the	pharmacologic	agents	that	
are	being	employed	to	do	not	predispose	our	test	subjects	to	hemorrhagic	
transformations.		
	 		
HYPOTHESIS	
	 This	study	seeks	to	test	the	hypothesis	that	the	administration	of	
simvastatin	in	a	pre‐stroke	environment,	followed	by	the	administration	of	the	
three	aforementioned	pharmacologic	agents	at	different	time	periods	in	a	post‐
stroke	environment	will	reduce	the	size	of	an	ischemic	infarct	and	reduce	the	
size	and	frequency	of	hemorrhagic	transformations.		
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SPECIFIC	AIMS	
	 The	focus	of	this	study	is	to	determine	whether	a	combination	of	
fluoxetine,	simvastatin	and	ascorbic	acid	has	an	impact	on	the	size	of	an	induced	
ischemic	infarct	and	on	the	size	and	frequency	of	a	secondary	hemorrhagic	
infarct.	This	study	will	also	seek	to	test	whether	or	not	the	timing	of	
administration	of	post‐stroke	pharmacologic	agents	has	any	bearing	on	the	size	
of	ischemic	infarcts	or	the	size	and	frequency	of	hemorrhagic	transformations.		
The	results	of	this	work	will	help	further	the	evidence	that	the	aforementioned	
pharmacologic	agents	have	utility	in	the	treatment	of	post	stroke	patients.	
	 Initially,	all	rats	received	simvastatin	for	7	days	pre‐stroke.	The	rats	then	
underwent	neurosurgery	to	induce	an	ischemic	infarct.	Then,	the	rats	were	
separated	into	two	different	groups:	a	group	that	received	the	three	
aforementioned	pharmacologic	agents	and	a	control	group	that	receives	only	
simvastatin.	Within	the	group	that	receives	the	three	aforementioned	
pharmacologic	agents,	there	will	be	sub‐groups	that	will	start	their	
pharmacologic	regimens	at	different	times	post‐stroke.	Once	pharmacologic	
analysis	is	complete,	the	rats	will	be	euthanized	and	their	brains	will	be	
removed,	preserved,	sliced	and	mounted	for	histological	analysis.	This	analysis	
will	allow	for	the	measuring	of	initial	ischemic	infarct	size	as	well	as	the	size	and	
frequency	of	hemorrhagic	transformations.			
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II.	MATERIALS	AND	METHODS	
All	studies	in	this	paper	were	performed	in	accordance	with	protocols	
approved	by	the	Wright	State	University	Institutional	Animal	Care	and	Use	
Committee	(IACUC).	
	
Pre‐stroke	simvastatin	
	 The	pharmacologic	agents	for	this	experiment	come	in	powder	form.	In	
order	to	administer	the	agents	to	the	rats,	the	dosages	of	each	agent	were	
weighed	and	then	placed	into	balls	of	sugar	cookie	dough.	This	methodology	
provided	a	voluntary	means	of	delivering	the	pharmacologic	agents	to	the	rats.	
All	rats	received	1	milligram/kilogram	of	simvastatin	once	a	day	for	seven	days	
before	the	induction	of	the	stroke.		
	
STROKE	INDUCTION	
	 Strokes	were	induced	in	all	rats	using	surgical	techniques.	Endothelin,	a	
potent	vasoconstrictor,	was	injected	into	the	forelimb	motor	cortex	of	the	right	
hemisphere	(causing	motor	deficits	in	the	left	forelimb).	The	stereotactic	
coordinates	were	measured	from	the	bregma	of	the	skull	(the	bregma	is	the	
fusion	point	for	multiple	bones	that	compose	the	skull).		
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Pre‐operative	care	
	 The	rat	is	placed	into	an	induction	chamber	and	is	put	to	sleep	with	5%	
isoflurane,	an	anesthetic	gas.	Once	the	rat	is	unconscious,	the	animal	is	removed	
and	the	head	is	shaved.	The	rat	is	then	placed	in	a	stereotactic	device	to	secure	
the	skull	in	a	stable	position.	A	heating	pad	is	placed	underneath	the	animal	to	
maintain	body	temperature,	and	a	gas	mask	administering	2‐3%	isoflurane	gas	
is	placed	over	the	nose	and	mouth	of	the	rat	for	the	duration	of	the	procedure.	
Puralube	eye	ointment	is	applied	to	prevent	abrasions	to	the	cornea,	and	a	foot‐
pinch	withdrawal	reflex	is	employed	to	ensure	full	anesthetization.		
	
Surgical	procedure	
	 The	incision	site	on	top	of	the	skull	is	initially	cleaned	with	povidone‐
iodine,	an	antiseptic	substance.	The	incision	site	is	then	cleaned	with	ethanol	
(another	antiseptic)	and	then	scrubbed	with	povidone‐iodine.	This	three‐step	
application	of	antiseptic	substances	ensures	that	the	surgical	site	is	as	free	of	
microbial	contaminants	as	possible,	and	limits	the	possibility	of	a	post‐surgical	
infection.	
	 A	midline	incision	is	made	on	the	superior	part	of	the	rat’s	head,	and	the	
edges	of	the	incision	are	dabbed	with	bupivacaine.	Bupivacaine	is	a	local	
analgesic	that	decreases	sensation	at	the	incision	site.	By	decreasing	the	
sensation,	the	rats	will	be	less	likely	to	scratch	the	incision	site	and	tear	away	the	
sutures.	Once	the	skull	is	exposed,	bregma	is	located	and	marked	with	a	fine‐tip	
marker.	Next,	a	microdrill	is	aligned	to	the	pen	mark.	An	anatomical	guidebook	
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was	then	used	to	note	the	coordinates	of	the	motor	cortex.	The	drill	was	initially	
moved	to	the	right	(‐2.5	millimeters	in	the	medial‐lateral	plane),	and	a	hole	was	
then	drilled	through	the	entire	superior	portion	of	the	skull.	The	drill	was	then	
moved	forward	(+1.5	millimeters	in	the	anterior‐posterior	plane)	and	a	second	
hole	was	then	drilled.	Once	both	holes	were	drilled,	the	drill	was	replaced	with	a	
Hamilton	syringe	containing	endothelin	at	a	concentration	of	400	
picomoles/microliter.	The	syringe	was	inserted	into	one	hole	to	a	depth	of	2	
millimeters,	and	then	endothelin	was	administered	in	0.1	microliter	increments	
over	the	course	of	several	minutes	until	1.5	microliters	had	been	administered.	
The	syringe	is	then	removed,	and	the	process	is	repeated	for	the	other	hole.	Once	
endothelin	had	been	administered	to	both	holes,	the	surgical	site	was	closed	
with	resorbable	sutures.	Povidone‐iodine	was	applied	to	the	incision	site	one	
final	time.		
	
Post‐Operative	Care	
	 Two	milliliters	of	subcutaneous	saline	was	injected	into	the	animal	before	
placing	the	animal	into	a	cage	with	a	heating	pad	to	recover	from	anesthesia.	
Once	the	rat	began	voluntary	movements,	it	was	placed	back	into	its	holding	
cage.	
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POST‐STROKE	TREATMENT	
Pharmacologic	agents	
The	sugar	cookie	dough	method	employed	to	administer	the	simvastatin	
pre‐stroke	was	also	employed	to	administer	pharmacologic	agents	post	stroke.		
The	pharmacologic	regimen	consisted	of	5	milligrams/kilogram	of	fluoxetine,	1	
milligram/kilogram	of	simvastatin	and	20	milligrams/kilogram	of	vitamin	C.	
Twelve	rats	initiated	this	regimen	6‐12	hours	after	the	stroke	surgery.	Nine	rats	
initiated	the	same	pharmacologic	regimen	20‐26	hours	after	the	stroke	surgery.	
Nine	rats	initiated	the	pharmacologic	regimen	48‐54	hours	after	the	stroke	
surgery.	The	remaining	ten	rats	continued	their	simvastatin‐only	regimen	that	
was	started	before	the	surgery.	The	simvastatin‐only	group	initiated	their	
medication	20‐26	hours	after	stroke	surgery.	Once	initiated,	all	rats	received	a	
single	dose	of	their	assigned	pharmacologic	regimens	once	a	day	for	six	days.	
	
INFARCT	ANALYSIS	
Euthanization	
	 Animals	were	euthanized	with	an	injection	of	100	milligrams/kilogram	of	
sodium	pentobarbital	on	post‐stroke	day	7.	The	chest	cavity	of	the	animal	was	
then	cut	open,	exposing	the	heart.	Two	incisions	were	made	into	the	heart	to	
allow	the	animal	to	exsanguinate.	The	tissue	of	the	animal	was	then	perfused	
with	100	milliliters	of	phosphate	buffered	solution	and	fixed	using	a	4%	
paraformaldehyde‐in‐phosphate	buffered	solution.		
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	 Once	the	animals	were	deceased,	the	brains	were	removed	and	placed	in	
a	4%	paraformaldehyde	solution	overnight,	followed	by	a	30%	sucrose	solution	
for	three	days.		
	
Cryostat	Sectioning	of	Brain	Tissue	
	 The	brain	tissue	is	set	in	an	Optimal	Cutting	Temperature	compound	and	
then	frozen	using	a	Peltier	device	on	the	cryostat.	After	30	minutes,	the	frozen	
tissue	is	placed	into	the	cryostat	and	sliced	into	50‐micrometer	thick	coronal	
sections.	Every	sixth	section	was	placed	sequentially	into	one	of	six	vials	
containing	phosphate	buffered	solution.		
	
Slide	preparation	
	 In	order	to	analyze	the	brain	tissue	for	both	infarct	size	and	hemorrhagic	
transformation,	the	brain	sections	were	mounted	onto	glass	slides	and	stained	
with	hematoxylin	and	eosin.		
	
Tissue	Mounting	
	 The	brain	slices	were	poured	into	petri	dishes	containing	phosphate	
buffered	solution.	Microscope	slides	are	labeled	with	the	corresponding	number	
of	the	rat	and	the	stain	that	will	be	employed	to	color	the	sections.	The	slides	are	
placed	into	the	petri	dishes	at	an	angle,	and	then	fine‐tip	paintbrushes	are	used	
to	maneuver	the	tissue	sections	onto	the	glass	slides.	The	slides	are	then	set	
aside	to	dry.		
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Staining	
	 After	the	sections	have	dried,	the	slides	are	placed	into	slide	racks.	Tissue	
is	then	stained	using	a	hematoxylin	solution	and	a	0.5%	eosin	solution.	The	slices	
are	stained	using	a	series	of	timed	washes:	hematoxylin	for	fifteen	minutes,	
warm	running	tap	water	for	fifteen	minutes,	distilled	water	for	thirty	seconds,	
95%	ethanol	for	thirty	seconds,	eosin	for	one	minute,	two	washes	of	95%	
ethanol	for	two	minutes	each,	two	washes	of	100%	ethanol	for	two	minutes	each	
and	two	washes	of	xylene	for	two	minutes	each.	The	slides	were	allowed	to	dry,	
and	then	cover	slips	were	placed	over	the	tissue	and	sealed	onto	the	slides	by	
using	a	mordant.	
	
Image	Capture	and	Analysis	
	 The	slides	were	analyzed	using	OMAX	video	microscopes.	Slides	were	
examined	under	brightfield	using	the	4x	scan	objective	lens.	The	video	
microscopes	were	connected	with	personal	computers,	and	pictures	of	the	brain	
tissue	were	taken	using	the	AmScope	software	program.	Once	taken,	multiple	
pictures	would	be	coalesced	into	a	single	image	using	Adobe	Photoshop	
software.	This	allows	for	the	viewing	of	the	entire	infarct	in	a	single	image.	Then,	
the	ImageJ	software	program	was	used	to	trace	and	calculate	the	area	of	the	
ischemic	and	hemorrhagic	transformations	(recorded	in	millimeters	square).	
The	brain	sections	only	provided	the	area	of	the	infarct	in	a	two‐dimensional	
space.	In	order	to	calculate	the	three‐dimensional	volume	of	the	infarct,	the	
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measured	areas	for	each	individual	rat	were	summated,	multiplied	by	0.05	
(because	the	tissue	sections	were	0.05	millimeters	thick)	and	then	multiplied	by	
6	(because	every	sixth	slice	of	brain	tissue	was	used	for	capturing	infarct	data).	
The	resulting	number	provided	the	total	infarct	volume	(recorded	in	millimeters	
cubed).	
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III.	RESULTS		
	
EXPERIMENT	RESULTS	
Infarct	Size	
	 The	infarct	volumes	of	each	rat	were	calculated	by	measuring	the	two‐
dimensional	areas	of	each	infarct,	summating	the	areas,	then	multiplying	the	
summations	by	0.05	and	then	by	6	(Table	1).	The	calculated	volumes	were	
tabled	by	group	(the	control	group	plus	the	three	groups	defined	by	the	timing	of	
the	initiation	of	pharmacologic	intervention)	(Table	2).	Group	1	initiated	
pharmacologic	treatment	at	6‐12	hours	post‐stroke,	group	2	initiated	
pharmacologic	treatment	20‐26	hours	post‐stroke,	group	3	initiated	
pharmacologic	treatment	48‐54	hours	post	stroke.	In	order	to	control	for	bias,	
the	researchers	were	blind	to	the	group	identities	until	infarct	volumes	were	
measured.	The	infarct	volume	means	for	each	group	were	calculated	along	with	
a	plus‐or‐minus	for	the	standard	error	of	the	mean.	The	calculated	infarct	
volume	mean	for	group	1	was	20.17	±	5.585	millimeters	cubed.		For	group	2,	it	
was	15.67	±	5.622	millimeters	cubed.	For	group	3,	it	was	39.18	±	12.15	
millimeters	cubed.		For	the	control	group,	it	was	35.57	±	8.632	millimeters	
cubed.	Initially,	the	means	of	all	four	groups	were	compared	using	an	ordinary	
one‐way	analysis	of	variance.	The	initial	analysis	indicated	that	there	was	no	
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significant	statistical	difference	between	the	means	of	the	control	group	
compared	to	any	of	the	means	for	the	drug‐treatment	groups	(p‐value	=	0.1716)	
(Graph	1).	Following	the	initial	analysis,	each	group	was	individually	compared	
to	the	control	group	using	an	unpaired	t‐test	with	a	Welsch’s	correction.		There	
was	no	statistical	difference	between	any	of	the	three	groups	when	individually	
compared	to	the	control	group	(p‐values	=	0.1552,	0.0722	and	0.8122	
respectively)	(Graph	1).	The	data	was	then	analyzed	for	any	outliers	that	were	
potentially	confounding	the	data.	Two	data	points	from	group	2	were	identified	
as	outliers	and	removed	from	the	data	(Table	3).	When	the	outliers	were	
removed	from	group	2,	an	ordinary	one‐way	analysis	of	variance	comparing	the	
means	for	all	four	groups	yielded	a	p‐value	of	0.0651	(which	is	borderline	
significant).	When	group	2	was	again	compared	to	the	control	group	in	an	
unpaired	t‐test	with	a	Welsch’s	correction,	the	results	indicated	that	there	was	a	
statistically	significant	decrease	in	infarct	size	(p‐value	=	0.0098)	(Graph	2).	
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Table	1	
Tables	showing	how	the	two	dimensional	infarct	areas	were	documented	and	
how	the	three	dimensional	infarct	volumes	were	calculated.	The	leftmost	column	
indicates	the	numerical	designation	of	the	rat.	Two	different	microscopes	with	
differing	resolutions	were	used	during	the	experiment,	so	the	microscope	that	
was	used	to	analyze	each	microscope	slide	was	identified.	The	amount	of	tissue	
that	was	obtained	from	a	single	rat	was	typically	more	than	could	be	placed	onto	
a	single	microscope	slide,	so	multiple	slides	were	used	and	numbered.	Finally,	
individual	pieces	of	tissue	were	numbered	by	their	arrangement	on	the	slide,	
with	the	section	closest	to	the	slide	label	designated	section	number	1.		It	is	
important	to	note	that	not	all	sections	of	brain	tissue	had	an	observable	infarct,	
and	that	some	microscope	slides	did	not	have	a	single	tissue	section	with	an	
infarct.	The	infarct	volume	was	calculated	by	taking	the	individual	infarct	areas,	
multiplying	that	number	by	0.05	(because	the	sections	are	0.05	millimeters	
thick),	and	then	multiplying	again	by	6	(because	every	sixth	section	was	taken	
for	calculating	infarct	data).	The	final	numerical	value	in	the	last	row	is	a	
summation	of	the	calculated	infarcts.	
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Table	1	
rat  scope  slide  section  area (mm2)  volume (mm3) 
852  2  4  1  21.463 6.4389 
852  2  4  2  16.471 4.9413 
852  2  4  3  12.316 3.6948 
852  2  4  5  17.255 5.1765 
852  2  4  6  10.233 3.0699 
852  Number of tissue sections: 5  23.3214 
853  2  1  1  5.456 1.6368 
853  2  1  2  3.551 1.0653 
853  2  1  3  2.489 0.7467 
853  2  1  4  7.094 2.1282 
853  2  2  1  3.023 0.9069 
853  2  2  2  5.179 1.5537 
853  2  2  3  8.372 2.5116 
853  2  2  4  2.874 0.8622 
853  2  2  5  7.393 2.2179 
853  2  3  1  6.74 2.022 
853  2  3  2  6.885 2.0655 
853  2  3  3  9.708 2.9124 
853  2  4  2  0.726 0.2178 
853  2  4  3  0.638 0.1914 
853  Number of tissue sections: 14  21.0384 
854  2  1  1  2.361 0.7083 
854  2  1  2  11.178 3.3534 
854  2  1  3  12.762 3.8286 
854  2  2  1  8.356 2.5068 
854  2  2  2  7.604 2.2812 
854  2  2  3  8.258 2.4774 
854  2  2  4  5.874 1.7622 
854  2  2  5  5.01 1.503 
854  2  3  2  3.265 0.9795 
854  2  3  3  1.655 0.4965 
854  2  3  4  3.873 1.1619 
854  2  4  1  4.77 1.431 
854  2  4  2  4.459 1.3377 
854  2  4  3  8.312 2.4936 
854  2  4  4  8.319 2.4957 
854  Number of tissue sections: 15  28.8168 
855  2  1  1  1.136 0.3408 
855  Number of tissue sections: 1  0.3408 
856  2  1  1  25.441 7.6323 
856  2  1  3  10.528 3.1584 
856  2  1  4  12.752 3.8256 
856  2  2  1  11.542 3.4626 
	 41
856  2  2  2  12.157 3.6471 
856  2  2  3  10.772 3.2316 
856  2  2  4  10.532 3.1596 
856  2  2  5  14.347 4.3041 
856  2  3  1  10.504 3.1512 
856  2  3  2  11.225 3.3675 
856  2  3  3  14.339 4.3017 
856  2  3  4  10.439 3.1317 
856  2  3  5  9.143 2.7429 
856  Number of tissue sections: 13  49.1163 
857  2  1  1  4.662 1.3986 
857  2  1  3  1.448 0.4344 
857  2  1  4  1.124 0.3372 
857  2  2  1  0.952 0.2856 
857  2  2  2  1.462 0.4386 
857  2  2  5  4.308 1.2924 
857  2  4  1  5.255 1.5765 
857  Number of tissue sections: 7  5.7633 
859  2  1  1  13.398 4.0194 
859  2  1  2  9.49 2.847 
859  2  1  3  10.83 3.249 
859  2  1  4  13.894 4.1682 
859  2  1  5  15.839 4.7517 
859  2  3  1  1.036 0.3108 
859  2  3  2  2.479 0.7437 
859  2  3  3  8.869 2.6607 
859  2  3  4  5.666 1.6998 
859  2  3  6  3.722 1.1166 
859  2  3  7  2.711 0.8133 
859  Number of tissue sections: 11  26.3802 
861  2  1  4  4.284 1.2852 
861  2  2  3  4.394 1.3182 
861  2  3  2  3.391 1.0173 
861  2  3  3  4.635 1.3905 
861  2  4  5  5.294 1.5882 
861  Number of tissue sections: 5  6.5994 
862  2  1  2  2.538 0.7614 
862  2  1  3  2.948 0.8844 
862  2  1  4  3.775 1.1325 
862  2  2  1  2.385 0.7155 
862  2  2  3  3.996 1.1988 
862  2  2  4  3.411 1.0233 
862  2  3  1  3.82 1.146 
862  2  3  2  4.5 1.35 
862  2  3  4  3.495 1.0485 
862  2  4  1  3.53 1.059 
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862  2  4  3  4.398 1.3194 
862  Number of tissue sections: 11  11.6388 
864  2  1  3  1.104 0.3312 
864  2  2  3  1.644 0.4932 
864  2  3  4  0.962 0.2886 
864  Number of tissue sections: 3  1.113 
865  2  1  1  11.746 3.5238 
865  2  1  2  13.521 4.0563 
865  2  2  1  11.526 3.4578 
865  2  2  2  11.833 3.5499 
865  2  2  3  8.788 2.6364 
865  2  2  4  12.153 3.6459 
865  2  3  1  15.131 4.5393 
865  2  3  2  9.445 2.8335 
865  2  3  3  7.442 2.2326 
865  2  3  4  10.843 3.2529 
865  2  4  1  8.734 2.6202 
865  2  4  2  7.307 2.1921 
865  2  4  3  12.005 3.6015 
865  2  4  4  9.919 2.9757 
865  Number of tissue sections: 14  45.1179 
866  2  1  1  6.252 1.8756 
866  2  1  2  4.622 1.3866 
866  2  1  3  3.425 1.0275 
866  2  2  2  5.803 1.7409 
866  2  2  3  7.219 2.1657 
866  2  3  1  2.008 0.6024 
866  2  4  2  0.866 0.2598 
866  Number of tissue sections: 7  9.0585 
868  2  5  1  12.444 3.7332 
868  2  5  2  16.536 4.9608 
868  2  5  3  12.643 3.7929 
868  Number of tissue sections: 3  12.4869 
869  2  1  3  4.428 1.3284 
869  2  1  4  2.617 0.7851 
869  2  1  5  6.044 1.8132 
869  2  2  1  5.933 1.7799 
869  2  2  2  2.101 0.6303 
869  Number of tissue sections: 5  6.3369 
870  2  2  3  1.212 0.3636 
870  2  5  1  2.066 0.6198 
870  2  5  2  1.069 0.3207 
870  2  5  3  1.824 0.5472 
870  2  5  4  1.335 0.4005 
870  Number of tissue sections: 5  2.2518 
872  2  2  1  6.902 2.0706 
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872  2  2  4  1.914 0.5742 
872  2  3  5  7.319 2.1957 
872  2  4  1  13.332 3.9996 
872  Number of tissue sections: 4  8.8401 
873  2  1  1  13.202 3.9606 
873  2  1  2  9.656 2.8968 
873  2  1  3  10.082 3.0246 
873  2  1  4  13.786 4.1358 
873  2  4  1  9.813 2.9439 
873  2  4  2  17.651 5.2953 
873  2  4  4  8.76 2.628 
873  2  5  1  20.266 6.0798 
873  2  5  2  19.791 5.9373 
873  2  5  3  11.7 3.51 
873  2  5  4  12.552 3.7656 
873  Number of tissue sections: 11  44.1777 
874  2  1  1  7.26 2.178 
874  2  1  2  4.362 1.3086 
874  2  1  3  6.253 1.8759 
874  2  1  4  6.001 1.8003 
874  2  2  2  2.098 0.6294 
874  2  2  4  4.63 1.389 
874  2  4  4  2.712 0.8136 
874  2  6  1  5.577 1.6731 
874  2  6  3  3.533 1.0599 
874  2  6  4  9.384 2.8152 
874  Number of tissue sections: 10  15.543 
875  2  1  2  5.907 1.7721 
875  2  1  4  4.101 1.2303 
875  2  2  1  9.716 2.9148 
875  2  2  2  10.891 3.2673 
875  2  2  3  13.238 3.9714 
875  2  2  4  8.505 2.5515 
875  2  2  5  12.712 3.8136 
875  2  3  1  11.763 3.5289 
875  2  3  2  9.777 2.9331 
875  2  3  3  8.104 2.4312 
875  2  3  4  6.664 1.9992 
875  2  3  5  10.576 3.1728 
875  2  4  1  5.493 1.6479 
875  2  4  2  11.057 3.3171 
875  2  4  3  10.597 3.1791 
875  2  4  4  8.299 2.4897 
875  2  4  5  13.064 3.9192 
875  Number of tissue sections: 17  48.1392 
876  2  1  1  2.907 0.8721 
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876  2  2  1  1.283 0.3849 
876  2  3  1  1.15 0.345 
876  2  4  5  2.533 0.7599 
876  2  5  1  2.9 0.87 
876  2  5  3  2.017 0.6051 
876  2  5  4  2.721 0.8163 
876  Number of tissue sections: 7  4.6533 
879  1  2  3  31.983 9.5949 
879  1  2  4  37.966 11.3898 
879  1  3  1  38.465 11.5395 
879  1  3  2  38.277 11.4831 
879  2  1  1  12.879 3.8637 
879  2  1  2  12.73 3.819 
879  2  1  3  3.996 1.1988 
879  2  2  5  1.336 0.4008 
879  Number of tissue sections: 8  53.2896 
880  1  1  1  14.565 4.3695 
880  1  1  3  16.771 5.0313 
880  1  1  5  9.486 2.8458 
880  1  2  1  10.373 3.1119 
880  1  2  2  24.375 7.3125 
880  1  2  3  3.19 0.957 
880  1  2  4  7.284 2.1852 
880  1  2  5  5.913 1.7739 
880  1  3  4  4.593 1.3779 
880  Number of tissue sections: 9  28.965 
881  1  1  1  18.846 5.6538 
881  1  1  2  15.932 4.7796 
881  1  1  4  18.24 5.472 
881  1  1  5  29.651 8.8953 
881  1  2  1  18.908 5.6724 
881  1  2  2  36.617 10.9851 
881  1  2  3  42.935 12.8805 
881  1  2  4  17.879 5.3637 
881  Number of tissue sections: 8  59.7024 
883  1  1  1  5.161 1.5483 
883  1  1  2  8.286 2.4858 
883  1  1  3  7.551 2.2653 
883  1  2  2  8.081 2.4243 
883  1  3  1  9.714 2.9142 
883  1  3  3  7.737 2.3211 
883  Number of tissue sections: 6  13.959 
884  1  1  2  10.285 3.0855 
884  1  1  4  37.974 11.3922 
884  1  2  1  57.457 17.2371 
884  1  2  2  35.034 10.5102 
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884  1  2  3  62.457 18.7371 
884  1  2  4  70.882 21.2646 
884  1  3  1  15.813 4.7439 
884  1  3  2  46.98 14.094 
884  1  3  3  62.476 18.7428 
884  Number of tissue sections: 9  119.8074 
885  1  2  3  28.463 8.5389 
885  Number of tissue sections: 1  8.5389 
886  1  1  2  8.004 2.4012 
886  1  1  3  14.697 4.4091 
886  1  1  4  14.041 4.2123 
886  1  2  2  7.287 2.1861 
886  1  3  3  8.207 2.4621 
886  1  4  4  8.958 2.6874 
886  Number of tissue sections: 6  18.3582 
887  1  1  3  19.506 5.8518 
887  1  1  4  19.664 5.8992 
887  1  2  1  17.272 5.1816 
887  1  2  3  9.071 2.7213 
887  1  2  5  4.649 1.3947 
887  1  3  2  22.716 6.8148 
887  1  3  3  18.22 5.466 
887  1  3  4  31.54 9.462 
887  Number of tissue sections: 8  42.7914 
888  1  1  2  3.411 1.0233 
888  1  1  4  1.553 0.4659 
888  1  2  1  8.358 2.5074 
888  1  2  2  5.387 1.6161 
888  1  2  4  2.713 0.8139 
888  1  4  1  2.616 0.7848 
888  1  4  3  1.97 0.591 
888  Number of tissue sections: 7  7.8024 
889  1  1  1  9.328 2.7984 
889  2  1  2  6.988 2.0964 
889  2  3  5  9.878 2.9634 
889  Number of tissue sections: 3  7.8582 
891  1  1  1  19.764 5.9292 
891  1  1  2  33.341 10.0023 
891  1  1  3  30.537 9.1611 
891  1  1  4  44.716 13.4148 
891  1  1  5  15.236 4.5708 
891  1  2  1  48.479 14.5437 
891  1  2  2  47.514 14.2542 
891  1  2  3  16.004 4.8012 
891  1  2  4  25.751 7.7253 
891  1  2  5  14.42 4.326 
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891  1  2  6  21.569 6.4707 
891  Number of tissue sections: 11  95.1993 
892  2  1  1  10.004 3.0012 
892  2  1  2  7.717 2.3151 
892  2  1  3  11.019 3.3057 
892  2  1  5  8.608 2.5824 
892  2  2  1  11.685 3.5055 
892  2  2  2  21.28 6.384 
892  2  2  3  14.209 4.2627 
892  2  2  4  11.638 3.4914 
892  2  2  5  18.958 5.6874 
892  2  3  2  13.595 4.0785 
892  2  3  3  16.017 4.8051 
892  Number of tissue sections: 11  43.419 
893  2  1  1  13.838 4.1514 
893  2  1  2  11.016 3.3048 
893  2  1  3  17.986 5.3958 
893  2  1  4  17.936 5.3808 
893  2  2  1  5.626 1.6878 
893  2  2  2  17.32 5.196 
893  2  2  3  16.927 5.0781 
893  2  2  4  17.28 5.184 
893  2  3  1  11.222 3.3666 
893  2  3  2  8.914 2.6742 
893  Number of tissue sections: 10  41.4195 
895  2  1  1  4.376 1.3128 
895  2  1  2  12.639 3.7917 
895  2  1  3  9.656 2.8968 
895  2  1  4  10.784 3.2352 
895  2  1  5  2.756 0.8268 
895  2  2  1  9.218 2.7654 
895  2  2  2  11.659 3.4977 
895  2  2  3  3.834 1.1502 
895  2  2  4  16.357 4.9071 
895  2  2  5  10.292 3.0876 
895  2  3  1  13.429 4.0287 
895  2  3  2  11.561 3.4683 
895  2  3  3  8.663 2.5989 
895  2  3  4  13.227 3.9681 
895  Number of tissue sections: 14  41.5353 
896  2  1  3  9.251 2.7753 
896  2  1  4  6.989 2.0967 
896  2  1  5  3.442 1.0326 
896  Number of tissue sections: 3  5.9046 
897  2  1  1  11.29 3.387 
897  2  1  2  18.493 5.5479 
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897  2  1  3  19.626 5.8878 
897  2  1  4  16.781 5.0343 
897  2  2  1  12.817 3.8451 
897  2  2  3  8.457 2.5371 
897  2  3  1  26.826 8.0478 
897  2  3  2  27.437 8.2311 
897  2  3  3  11.888 3.5664 
897  2  3  4  7.124 2.1372 
897  2  3  5  10.692 3.2076 
897  Number of tissue sections: 11  51.4293 
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Table	2	
Table	showing	the	total	number	of	calculated	infarct	volumes	(in	millimeters	
cubed)	for	all	four	groups	of	rats.	Each	cell	contains	an	infarct	volume	for	a	
particular	rat.	All	groups	of	rats	received	one	milligram/kilogram	of	simvastatin	
once	a	day	for	six	days	pre‐stroke.	Groups	1‐3	received	five	milligrams/kilogram	
of	fluoxetine,	one	milligram/kilogram	of	simvastatin	and	twenty	
milligrams/kilogram	of	vitamin	C	once	a	day	for	six	days	after	the	stroke	was	
induced.	The	groups	were	then	defined	by	when	the	pharmacologic	regimen	was	
initiated.	For	group	1,	the	regimen	was	initiated	6‐12	hours	after	stroke	
induction.	For	group	2,	the	regimen	was	initiated	20‐26	hours	after	stroke	
induction,	and	for	group	3,	the	regimen	was	initiated	48‐54	hours	after	stroke	
induction.	The	control	group	only	received	the	same	single	dose	of	simvastatin	
that	was	received	pre‐stroke.	The	control	group	received	their	dose	once	a	day	
for	six	days,	and	the	regimen	for	the	control	group	was	initiated	20‐26	hours	
after	stroke	induction.		
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Table	2	
Control	 Group	1	(6‐12hrs)	 Group	2	(24‐48	
hrs)	
Group	3	(48‐54	
hrs)	
18.3582	 23.3214	 11.6388	 15.543	
42.7914	 21.0384	 1.113	 48.1392	
7.8024	 28.8168	 45.1179	 4.6533	
7.8582	 0.3408	 9.0585	 53.2896	
95.1993	 49.1163	 12.4869	 28.965	
43.419	 5.7633	 6.3369	 59.7024	
41.4195	 26.3802	 2.2518	 13.959	
41.5353	 	 8.8401	 119.8074	
5.9046	 	 44.1777	 8.5389	
51.4293	 	 	 	
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Graph	1	
Graph	representing	an	analysis	of	the	infarct	volumes.	The	geometric	shapes	on	
the	graph	represent	the	infarct	volumes.	The	larger	horizontal	line	represents	
the	mean	of	the	values,	while	the	smaller	horizontal	lines	represent	the	
endpoints	for	the	range	of	the	standard	error	of	the	mean.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 51
Graph	1	
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Table	3	
Table	showing	the	infarct	volumes	for	group	2	with	outliers	removed.	The	table	
also	shows	the	control	infarct	volumes.	Compared	to	table	2,	two	values	from	
group	2	were	identified	as	outliers	and	removed.	These	values	were	45.1179	
millimeters	cubed	(the	third	value	from	group	2	in	table	2)	and	44.1777	
millimeters	cubed	(the	ninth	value	from	group	2	in	table	2).	
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Table	3	
Control	 Group	2	
18.3582	 11.6388	
42.7914	 1.113	
7.8024	 9.0585	
7.8582	 12.4869	
95.1993	 6.3369	
43.419	 2.2518	
41.4195	 8.8401	
41.5353	 	
5.9046	 	
51.4293	 	
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Graph	2	
Graph	analysis	of	the	infarct	data	without	outliers.	The	graph	only	includes	the	
control	and	group	2,	due	to	the	fact	that	only	group	2	had	any	outliers	to	remove.	
Compared	to	graph	1,	note	that	the	range	of	the	standard	error	of	the	mean	has	
decreased	for	group	2,	indicating	less	variance	between	the	data	points.		
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Graph	2	
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Frequency	and	Risk	of	Hemorrhagic	Transformation	
	 The	tissue	sections	were	also	analyzed	for	the	presence	of	hemorrhagic	
transformations.	Although	hemorrhagic	transformations	tend	to	be	much	larger	
than	primary	ischemic	infarcts,	and	tend	to	cause	more	damage	to	the	
surrounding	tissue,	the	only	definitive	indicator	of	whether	or	not	a	hemorrhagic	
transformation	has	occurred	is	the	presence	of	blood	on	the	tissue	section	
(Figures	1‐2).	The	number	of	rats	that	had	hemorrhagic	transformations	and	the	
number	of	rats	that	did	not	have	hemorrhagic	transformations	were	tallied	by	
group	(Table	4).	In	group	1,	five	out	of	eight	rats	had	evidence	of	hemorrhagic	
transformations.	In	group	2,	two	out	of	nine	rats	had	evidence	of	hemorrhagic	
transformations.	In	group	3,	five	out	of	nine	rats	had	evidence	of	hemorrhagic	
transformations.	In	the	control	group,	six	out	of	ten	rats	had	evidence	of	
hemorrhagic	transformations.	
Once	the	number	of	hemorrhagic	transformations	were	tallied,	the	
relative	risk	of	having	a	hemorrhagic	transformation	for	each	group	was	
calculated.	Relative	risk	is	an	epidemiological	statistic	that	is	used	to	measure	
the	probability	of	an	event	occurring	in	an	exposed	group	compared	to	an	
unexposed	group.	For	the	purposes	of	this	experiment,	the	three	groups	that	
received	fluoxetine,	simvastatin	and	vitamin	C	post‐stroke	are	considered	
exposed	groups,	while	the	control	group	is	the	unexposed	group.	The	relative	
risk	was	calculated	for	each	exposed	group.	To	calculate	relative	risk,	the	
number	of	events	that	occur	in	the	exposed	group	is	divided	by	the	total	number	
of	individuals	in	the	group.	Then,	the	same	calculation	is	made	for	the	control	
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group.	Dividing	the	first	number	into	the	second	yields	the	relative	risk	(Table	
4).		The	relative	risk	for	group	1	was	calculated	to	be	1.0147	(95%	confidence	
interval	0.4981	to	2.1783,	p‐value	=	0.9136).		For	group	2,	it	was	0.3704	(95%	
confidence	interval	0.0987	to	1.3905,	p‐value	=	0.1411).	For	group	3,	it	was	
0.9529	(95%	confidence	interval	0.4274	to	2.0059,	p‐value	= 0.8453).		
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Table	4	
	 Table	showing	which	rats	had	evidence	of	hemorrhagic	transformations,	
and	which	did	not.	Rats	are	identified	by	the	three	digit	number	that	is	outside	
the	parentheses.	The	three‐digit	numbers	in	parentheses	are	a	shorthand	
method	of	indicating	the	exact	tissue	section	in	which	a	hemorrhagic	infarct	was	
observed.	The	first	number	of	the	three‐digits	refers	to	the	microscope	used	to	
analyze	the	tissue	section.	The	second	number	refers	to	the	particular	
microscope	slide	that	the	tissue	section	was	mounted	on.	The	third	number	
refers	to	the	number	of	the	tissue	section	in	question,	starting	from	the	top	of	the	
slide	and	counting	downward.	For	example,	“242”	refers	to	a	tissue	section	that	
was	analyzed	with	microscope	number	2,	on	slide	number	4,	that	was	second	
from	the	top	of	the	slide.	
The	rats	are	separated	by	group,	and	the	relative	risk	for	each	group	is	
calculated.	Relative	risk	is	calculated	by	dividing	the	number	of	individuals	in	a	
group	who	had	hemorrhagic	transformations	by	the	total	number	of	individuals	
in	the	group.	The	same	calculation	is	made	for	the	control	group.	Finally,	the	first	
value	is	divided	into	the	second	value	to	yield	the	relative	risk.	For	example,	in	
group	1,	five	of	the	eight	rats	had	evidence	of	a	hemorrhagic	infarct.	Five	divided	
by	eight	is	0.625.	In	the	control	group,	six	of	the	ten	rats	had	evidence	of	
hemorrhagic	transformations.	Six	divided	by	ten	is	0.60.	0.625	divided	by	0.60	is	
1.0417.		
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Table	4	
Hemorrhage  No hemorrhage 
Group 1  852 (242, 244, 246)   855
853 (21, 214, 221, 225, 231, 233)  857
854 (212, 224)  861
856 (221, 213, 225, 233) 
859 (213, 214) 
Relative Risk = 1.0417 (95% 
confidence interval 0.4981 to 
2.1783, p‐value = 0.9136) 
Group 2  865 (212, 234, 241, 244)  862
873 (212)  864
866
868
869
870
872
Relative Risk = 0.3704 (95% 
confidence interval 0.0987 to 
1.3905, p‐value = 0.1411) 
Group 3  874 (214, 224, 264)  876
875 (243, 245)  880
879 (131,132,211, 212)  881
883 (113, 133)  885
884 (112, 122, 123, 124, 133) 
Relative Risk = 0.9259 (95% 
confidence interval 0.4274 to 
2.0059, p‐value = 0.8453) 
Control  886 (113)  888
887 (113, 121, 132, 133)  889
891 (114, 115)  896
892 (221, 223, 225, 232)  897
893 (213, 214) 
895 (212, 213, 214, 224, 225, 231, 233, 234) 
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Figure	1	
A	primary	ischemic	infarct.	Note	the	well‐circumscribed	borders	and	minimal	
damage	to	surrounding	tissue.	This	particular	image	is	from	rat	857,	slide	2,	
section	2.	It	was	analyzed	with	microscope	#2.	A	schematic	diagram	of	a	coronal	
section	of	a	rat	brain	is	included,	with	a	tracing	to	indicate	the	location	of	the	
infarct.	
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Figure	1	
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Figure	2	
A	secondary	hemorrhagic	infarct.	Although	the	significant	size	and	damage	to	
the	surrounding	tissue	is	apparent,	the	defining	characteristic	of	a	hemorrhagic	
infarct	is	the	presence	of	blood.	This	image	is	from	rat	884,	slide	3,	section	3.	It	
was	analyzed	with	microscope	#1.	A	schematic	diagram	of	a	coronal	section	of	a	
rat	brain	is	included,	with	a	tracing	to	indicate	the	location	of	the	infarct.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	 63
Figure	2	
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In	addition	to	relative	risk	analysis,	contingency	tables	were	created	
comparing	each	group	to	another	group.	Contingency	tables	are	used	to	analyze	
the	relationship	between	two	or	more	categorical	variables.	In	this	experiment,	
the	two	categorical	variables	are	the	nature	of	the	pharmacologic	treatment	and	
the	presence	of	hemorrhagic	transformations.		Specifically,	the	data	was	
analyzed	using	Fishers	exact	test	of	retrospective	data.		Fishers	exact	test	is	a	
method	of	analyzing	contingency	tables.	It	is	typically	employed	when	the	
sample	size	is	small,	and	when	data	can	be	classified	by	two	different	categories	
(again,	the	two	categories	being	the	nature	of	the	pharmacologic	intervention	
and	the	presence	or	absence	of	hemorrhagic	transformations).	Fishers	exact	test	
also	allows	for	exact	calculation	of	P‐values.	None	of	the	p‐values	derived	from	
the	contingency	tables	using	Fishers	exact	test	were	statistically	significant.	
Contingency	tables	comparing	group	1	to	the	control,	group	1	to	group	2	and	
group	3	to	the	control	all	yielded	p‐values	of	1.0000.	A	contingency	table	
comparing	group	2	to	group	3	yielded	a	p‐value	of	0.3348.	A	contingency	table	
comparing	group	2	to	the	control	yielded	a	p‐value	of	0.1698,	and	a	contingency	
table	comparing	group	1	to	group	2	yielded	a	p‐value	of	0.1534	(Table	5).		
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Table	5	
Contingency	tables	comparing	the	various	groups	to	one	another.	Each	group	is	
identified	by	two	variables.	The	x‐axis	defines	groups	by	the	pharmacological	
treatment	they	received,	while	the	y‐axis	defines	groups	by	the	presence	or	
absence	of	hemorrhagic	transformations.	The	numerical	values	in	each	graph	
indicate	the	number	of	rats	that	showed	evidence	of	hemorrhagic	
transformations.		P‐values	are	included,	as	they	indicate	whether	or	not	the	
pharmacologic	treatments	had	a	statistically	significant	impact	on	the	frequency	
of	hemorrhagic	transformations.		
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Table	5	
Group 1  Control  Total 
Hemorrhagic  5 6 11
No 
hemorrhagic  3 4 7
Total  8 10 18
P‐value: 
1.0000 
Group 1  Group 2  Total 
Hemorrhagic  5 2 7
No 
hemorrhagic  3 7 10
Total  8 9 17
P‐value: 
0.1534 
Group 1  Group 3  Total 
Hemorrhagic  5 5 10
No 
hemorrhagic  3 4 7
Total  8 9 17
P‐value: 
1.0000 
Group 2  Control  Total 
Hemorrhagic  2 6 8
No 
hemorrhagic  7 4 11
Total  9 10 19
P‐value: 
0.1698 
Group 2  Group 3  Total 
Hemorrhagic  2 5 7
No 
hemorrhagic  7 4 11
Total  9 9 18
P‐value: 
0.3348 
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Group 3  Control  Total 
Hemorrhagic  5 6 11
No 
hemorrhagic  4 4 8
Total  9 10 19
P‐value: 
1.0000 
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IV.	DISCUSSION	
	
RESULTS	SUMMARY	
	 The	results	of	this	experiment	indicate	that	the	administration	of	post‐
stroke	pharmacologic	agents	affects	the	size	of	ischemic	infarcts.	Another	
conclusion	that	can	be	drawn	is	that	the	timing	of	administration	is	pertinent	
when	administering	post‐stroke	pharmacologic	agents	in	terms	of	the	size	of	
ischemic	infarcts.	None	of	the	pharmacologic	interventions	seemed	to	make	any	
statistically	significant	difference	in	terms	of	the	frequency	of	hemorrhagic	
transformations,	however.	Finally,	the	results	of	this	experiment	call	into	
question	the	effectiveness	of	pre‐stroke	simvastatin	in	reducing	the	size	of	
ischemic	infarcts,	or	in	preventing	hemorrhagic	transformations.		
	
Effects	of	Post‐Stroke	Pharmacologic	Regimen		
	 Rats	who	underwent	a	pre‐stroke	regimen	of	simvastatin,	followed	by	a	
post‐stroke	pharmacologic	regimen	of	fluoxetine,	simvastatin	and	ascorbic	acid	
that	was	initiated	at	20‐26	hours	post‐stroke	saw	a	statistically	significant	
decrease	in	infarct	size	when	compared	to	the	control	group	(Graph	2).	Animals	
who	were	given	fluoxetine,	simvastatin	and	ascorbic	acid	6‐12	hours	post	stroke	
or	48‐54	hours	post‐stroke	did	not	show	a	statistically	significant	difference	
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when	compared	to	the	control	group.	These	findings	are	consistent	with	
previous	studies	that	this	lab	has	done	(Corbett	et	al,	2015).		
In	a	previous	study	from	this	lab,	the	mean	of	the	infarct	volumes	from	a	
group	of	rats	that	were	treated	with	5	milligrams/kilogram	of	fluoxetine	and	one	
milligram/kilogram	of	simvastatin	20‐26	hours	post‐stroke	was	shown	to	be	less	
than	that	of	an	untreated	control	group	(3.051	±	0.3447	millimeters	cubed	for	
the	treated	group	versus	6.277	±	0.14	millimeters	cubed	for	the	control	group	
that	was	given	nothing,	pre	or	post‐stroke)	(Balch	et	al,	2015).	Although	the	
eventual	results	of	this	experiment	are	similar	to	those	of	the	previous	
experiment,	it	is	worth	noting	that	the	size	of	the	infarcts	in	this	experiment	are	
considerably	larger,	both	for	the	treated	groups	and	the	control	groups,	when	
compared	to	the	previous	experiment.		 	
The	most	likely	explanation	is	that	the	previous	experiment	was	
conducted	for	90	days	post	stroke,	whereas	this	experiment	was	conducted	for	
only	six	days	post	stroke.	A	prolonged	period	of	post‐stroke	treatment	would	
have	allowed	for	a	greater	degree	of	neurogenesis	and	healing,	and	therefore,	
the	observable	size	of	the	infarct	would	be	smaller.		Another	possibility	is	that	
the	previous	study	from	this	lab	employed	female	rats,	while	the	current	study	
employed	male	rats.	There	are	a	litany	of	differences	between	male	and	female	
human	brains,	including	the	overall	size	of	the	brain,	the	size	of	various	areas,	
the	composition	of	neurons,	neurotransmitter	content,	receptor	morphology	and	
dendrite	receptors	(Joel	2011).	The	difference	between	male	and	female	
hormones	has	been	shown	to	play	a	significant	part	in	stroke	response.	When	
	 70
comparing	male	rats,	pre‐menopausal	female	rats	and	female	rats	with	their	
ovaries	removed,	pre‐menopausal	female	rats	had	the	best	response	to	an	
induced	ischemic	stroke.	They	showed	greater	cerebral	blood	flow	and	smaller	
infarct	volumes	compared	to	the	other	two	groups.		This	difference	in	outcomes	
was	attributed	to	the	production	of	endogenous	estrogen	(Alkayed	et	al,	1998).	
Attempting	to	ascertain	the	exact	anatomical	or	physiologic	reason	that	male	rat	
brains	suffer	from	larger	infarcts	is	beyond	the	scope	of	this	experiment,	but	an	
appropriate	first	step	would	be	to	conduct	parallel	trials	that	are	exactly	alike,	
with	the	only	difference	being	that	one	trial	employs	male	rats	and	one	trial	
employs	female	rats.		
This	experiment	also	employed	different	pharmacologic	agents	at	
different	time	periods.	In	the	previous	experiment,	there	was	no	pre‐stroke	
treatment	with	any	pharmacologic	agents,	whereas	in	this	experiment,	all	rats	
were	given	a	one	milligram/kilogram	dose	of	simvastatin	once	a	day	for	seven	
days.	Furthermore,	this	current	experiment	introduced	a	20	milligram/kilogram	
dose	of	vitamin	C,	whereas	the	previous	experiment	did	not	include	vitamin	C.	It	
is	difficult	to	tell	whether	or	not	the	introduction	of	new	pharmacologic	agents	
had	any	bearing	on	the	size	of	the	infarcts	compared	to	previous	experiments.	
The	only	way	to	be	sure	would	be	to	run	experiments	directly	comparing	groups	
who	received	pre‐stroke	simvastatin	with	those	that	did	not,	and	groups	that	
received	vitamin	C	with	those	that	did	not.		
The	success	of	the	pharmacologic	regimen	in	reducing	the	size	of	an	
ischemic	infarct	can	be	attributed	to	the	aspects	of	the	agents	that	were	
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previously	discussed.	Whether	it	is	anti‐inflammation,	neurogenesis,	or	
increased	cerebral	blood	flow,	the	pharmacologic	agents	that	were	employed	
have	numerous	properties	that	would	make	them	ideal	for	post‐stroke	
treatment.		These	findings	are	pertinent	because	the	amount	of	damage	that	a	
stroke	causes	has	direct	implications	on	the	capabilities	of	the	individual	post‐
stroke.	Because	the	functions	of	the	brain	are	localized	to	various	areas,	the	
more	brain	tissue	that	is	damaged,	the	more	deficits	an	individual	will	have.	In	
theory,	limiting	the	amount	of	tissue	that	is	damaged	by	a	stroke	will	limit	the	
disabilities	of	the	individual.		
	
Effects	of	Timing	the	Initiation	of	Pharmacologic	Treatment	on	Stroke	Infarct	
Area			
	 Although	the	pharmacologic	regimen	employed	has	shown	to	be	effective	
in	limiting	the	size	of	cerebral	infarcts,	there	is	another	factor	that	is	important	
to	consider	when	employing	pharmacologic	agents	post‐stroke.	As	can	be	
observed	from	the	data,	the	timing	of	the	initiation	of	the	pharmacologic	
regimen	is	pertinent.	The	20‐26	hour	window	was	the	only	time	frame	that	
yielded	a	statistically	significant	decrease	in	infarct	size.	The	pharmacologic	
regimen	administered	before	and	after	this	window	did	not	yield	statistically	
significant	results.		
This	pattern	was	also	shown	in	previous	experiments	from	this	lab.	In	a	
previous	experiment,	rats	who	were	given	5	milligrams/kilogram	of	fluoxetine	
and	one	milligram/kilogram	at	6‐12	hours	post‐stroke	had	larger	infarct	
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volumes	compared	to	the	untreated	control	groups	(15.24	±	4.26	millimeters	
cubed	for	the	treated	group	versus	9.775	±	2.786	millimeters	cubed	for	the	
untreated	control	group)	(Balch	et	al,	2015).	Although	the	group	1	rats	did	not	
have	larger	infarcts	then	the	control	group	in	this	experiment,	there	was	not	a	
statistically	significant	decrease	in	their	mean	infarct	volumes.	There	are	
multiple	possible	reasons	for	this.	First,	five	of	the	eight	infarcts	associated	with	
group	1	in	this	experiment	had	hemorrhagic	transformations	present	(Figure	2).	
As	noted	previously,	simvastatin	has	anti‐thrombotic	properties	(Endres	et	al,	
1998).	One	possibility	is	that	the	early	introduction	of	simvastatin	inhibits	
thrombosis	within	cerebral	tissue	and	predisposes	post‐infarct	tissue	to	
bleeding.	It	is	worth	noting	that	when	the	experiment	was	first	started,	the	initial	
pre‐stroke	simvastatin	dose	was	2	milligrams/kilogram	for	all	rats.	Three	of	the	
rats	developed	significant	nosebleeds;	the	simvastatin	was	immediately	stopped	
and	the	experiment	was	delayed	for	a	week	in	order	for	the	simvastatin	to	fully	
excreted	by	the	rats.	The	experiment	was	restarted	with	lowering	the	dose	of	
pre‐stroke	simvastatin	to	1	milligram/kilogram,	and	no	complications	arose.	The	
anti‐thrombotic	properties	of	simvastatin	are	global,	and	if	elevated	doses	are	
able	to	cause	bleeding	from	healthy	mucosal	membranes,	it	is	possible	that	
statins	may	predispose	tissue	that	has	been	compromised	to	hemorrhagic	
transformations.		
	Also	as	previously	noted,	simvastatin	promotes	vascular	endothelial	
growth	factor,	a	primary	protein	for	vasculogenesis	(Chen	et	al,	2003).	If	
introduced	too	early,	vascular‐endothelial	growth	factor	may	promote	
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vasculogenesis	into	tissue	whose	structure	is	compromised	by	an	ischemic	
infarct,	leading	to	a	collapse	of	new	blood	vessels	and	causing	a	secondary	
hemorrhagic	infarct.	Further	investigation	into	the	presence	of	vascular‐
endothelial	growth	factor	in	cerebral	tissue	that	has	been	treated	with	
simvastatin	would	be	warranted	in	order	to	confirm	this	hypothesis.		
	 Initiation	of	pharmacologic	agents	at	48‐54	hours	also	did	not	yield	a	
statistically	significant	decrease	in	infarct	size.	In	fact,	the	mean	of	the	volume	of	
the	infarcts	was	greater	for	group	3	when	compared	to	controls.	One	possible	
explanation	for	this	outcome	is	that	the	induction	of	the	pharmacologic	agents	
occurs	too	late	in	order	to	have	any	effect	on	post‐ischemic	neural	tissue.	As	
noted	previously,	fluoxetine	has	anti‐inflammatory	properties;	specifically,	it	
limits	the	migration	of	neutrophils	and	microglial	cells	into	a	post‐ischemic	
environment	(Lim	et	al,	2008).	During	inflammation,	neutrophils	arrive	within	
24	hours.	They	are	followed	by	T‐cells	and	macrophages	on	day	4,	and	then	
fibroblasts	on	day	7	(“Inflammation”	2016).	By	initiating	pharmacologic	
treatment	at	48‐54	hours,	the	window	of	opportunity	for	fluoxetine	to	affect	the	
migration	of	neutrophils	has	passed.	Fluoxetine	also	encourages	the	production	
of	antioxidants.	Many	of	these	white	blood	cells	are	sources	of	reactive	oxygen	
species;	by	administering	fluoxetine	too	late,	the	window	of	opportunity	for	
antioxidants	to	bind	to	reactive	oxygen	species	and	prevent	oxidative	damage	is	
missed	as	well.			
	
	
	 74
Effect	of	Pre‐Stroke	Simvastatin	Treatment	
	 As	previously	noted,	there	is	a	body	of	evidence	that	suggests	the	
effectiveness	of	pre‐treatment	with	statins	concerning	post‐ischemic	stroke	
mortality	and	motor	function	(Endres	et	al,	1998;	Marti‐Fabregas	et	al,	2004;	
Jonsson	et	al,	2001).	One	of	the	proposed	hypotheses	of	this	experiment	was	to	
determine	whether	or	not	there	is	strong	evidence	that	indicates	pre‐treatment	
with	statins	has	any	bearing	on	ischemic	infarct	volume.		
For	this	experiment,	the	control	group	received	one	milligram/kilogram	
of	simvastatin	daily	for	seven	days	pre‐stroke.	The	mean	infarct	size	for	the	
control	group	was	35.57	±	8.632	millimeters	cubed.	The	size	of	these	infarcts	
was	considerable,	especially	when	compared	to	previous	experiments.	In	a	
previous	experiment,	two	control	groups	did	not	receive	any	pharmacologic	
treatment,	pre	or	post‐stroke.		The	infarct	volumes	for	those	control	groups	
were	6.277	±	0.14	millimeters	cubed	and	9.775	±	2.786	millimeters	cubed,	
respectively.	At	first	glance,	it	appears	that	pre‐stroke	simvastatin	actually	leads	
to	larger	stroke	volumes.		However,	it	is	difficult	to	compare	results	from	the	
previous	experiment	to	results	of	the	current	experiment.		
First,	the	previous	experiment	employed	Nissl	stain,	compared	to	the	
hematoxylin	and	eosin	stain	that	was	employed	for	the	current	experiment.	
Hematoxylin	and	eosin	clearly	color	the	invading	neutrophils,	microglia	and	
macrophages	(Figures	1	and	2).	The	delineation	of	the	infarct	damage	is	easy	to	
see	and	measure.	Nissl	stain,	however,	does	not	stain	the	invading	cells,	and	
therefore,	does	not	clearly	demarcate	the	borders	of	the	stroke.	Using	Nissl	stain	
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makes	exact	measurement	of	the	stroke	area	more	difficult.	In	addition,	many	of	
the	tissue	samples	from	the	previous	experiment	had	torn	at	the	site	of	the	
stroke	induction,	so	some	of	the	measurements	had	to	be	presumed.	Also,	and	
again	worth	noting,	the	previous	experiment	was	conducted	for	90‐days	post‐
stroke,	whereas	the	current	experiment	was	only	conducted	for	6	days	post‐
stroke.	Finally,	in	the	current	experiment,	six	of	the	10	control	tissue	samples	
showed	evidence	of	large	hemorrhagic	transformations	(Figure	2).	These	results	
are	somewhat	in	contradiction	to	previous	studies	that	suggested	that	statins	
were	neuro‐protective,	and	that	individuals	who	were	takings	statins	had	
greater	functional	improvement	and	lower	mortality	rates	post	stroke.		
	
Effect	of	Pharmacologic	Treatment	on	the	Frequency	of	Hemorrhagic	
Transformations	
Rats	who	were	given	a	pharmacologic	regimen	of	fluoxetine,	simvastatin	
and	vitamin	C	post‐stroke,	initiated	at	20‐26	hours,	showed	a	significant	
decrease	in	the	relative	risk	of	hemorrhagic	transformations.	Rats	who	were	
given	the	same	pharmacologic	regimen	at	6‐12	hours	and	at	48‐54	hours	did	not	
show	a	significant	increase	or	decrease	in	the	risk	of	hemorrhagic	
transformations.	The	relative	risk	value	is	a	ratio	that	determines	the	probability	
of	an	event	occurring	in	an	exposed	group	versus	an	unexposed	group.	Clinical	
trials	frequently	use	relative	risk	to	measure	the	efficacy	of	new	medications	
compared	to	old	medications.	It	can	also	be	used	to	track	the	probability	of	side	
effects.	A	relative	risk	equivalent	to	1	means	that	there	is	no	risk	difference	
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between	two	groups,	while	a	relative	risk	less	than	one	means	that	an	event	is	
less	likely	to	occur	in	the	exposed	group	compared	to	the	control,	and	a	relative	
risk	greater	than	one	means	that	an	event	is	more	likely	to	occur	in	the	exposed	
group	compared	to	the	control.		
When	compared	to	the	control,	groups	1	and	3	had	calculated	relative	
risks	at	1.0417	and	0.9259,	respectively.	Because	both	of	these	values	are	close	
to	one,	it	indicates	that	initiating	pharmacologic	agents	at	either	6‐12	or	48‐54	
hours	does	not	have	an	appreciable	affect	on	either	increasing	or	decreasing	the	
risk	of	a	hemorrhagic	transformation.	For	group	2,	the	relative	risk	was	0.3704.	
Although	this	data	would	suggest	that	the	20‐26	hour	window	is	the	“sweet	
spot”	concerning	reducing	the	risk	of	hemorrhagic	transformations,	the	p‐values	
for	these	relative	risk	calculations	are	greater	than	0.05,	so	it	is	difficult	to	draw	
definitive	conclusions	from	this	data.	One	possible	reason	for	the	high	p‐values	
could	be	attributed	to	the	small	sample	size.	By	increasing	the	number	of	test	
subjects,	the	resulting	data	may	yield	statistically	significant	p‐values.	
	 The	notion	that	20‐26	hours	is	the	proverbial	“sweet	spot”	concerning	
minimizing	the	risk	of	hemorrhagic	transformations	is	further	supported	by	the	
data	from	the	contingency	tables.	Contingency	tables	were	employed	to	analyze	
the	data	of	this	experiment	because	they	can	help	find	interrelations	between	
two	variables.	For	this	experiment,	the	two	variables	were	the	nature	of	the	
pharmacologic	interventions	(both	in	terms	of	the	medication	administered	and	
the	timing	of	the	administration)	and	the	presence	of	hemorrhagic	
transformations.	In	order	to	ascertain	whether	or	not	any	correlation	was	
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statistically	significant,	a	p‐value	must	be	calculated.	Fisher’s	exact	test	is	a	
methodology	of	analyzing	contingency	tables.	It	was	designed	to	analyze	
categorical	data	that	can	be	classified	in	two	different	ways,	hence	it’s	utility	in	
this	experiment.	It	is	most	commonly	employed	in	two‐by‐two	contingency	
tables,	and	when	the	sample	size	is	small.	It	also	allows	for	the	exact	calculation	
of	the	p‐value.		
The	majority	of	the	contingency	tables	yielded	a	p‐value	of	one	(Table	5).	
Only	contingency	tables	that	involved	group	2	yielded	lower	p‐values,	although	
the	p‐values	were	still	greater	than	0.05.	The	fact	that	the	p‐values	did	decrease	
when	groups	were	compared	to	group	2	indicates	that	there	is	a	trend	towards	
the	validity	of	the	idea	that	the	20‐26	hour	window	is	the	most	ideal	when	
concerning	limiting	the	risk	of	hemorrhagic	transformations.	Similar	to	the	
relative	risk	data,	however,	is	that	because	the	p‐values	are	greater	than	0.05,	
the	notion	that	the	20‐26	hour	window	is	the	most	ideal	can	only	be	inferred;	it	
cannot	be	a	definitive	conclusion.	Again,	increasing	the	sample	size	would	help	
to	truly	ascertain	whether	or	not	the	trends	indicated	in	this	experiment	are	
viable.		
	 The	biological	reasoning	behind	these	findings	is	most	likely	similar	to	
the	previously	mentioned	reasoning	behind	the	differences	in	infarct	volume.	As	
previously	noted,	simvastatin	has	multiple	properties	that	would	predispose	an	
individual	to	hemorrhagic	transformations	if	implemented	too	soon,	including	
anti‐platelet	and	pro‐vasculogenesis	properties	(Endres	et	al,	1998;	Chen	et	al,	
2003).	By	administering	the	pharmacologic	regimen	too	late,	the	window	to	
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inhibit	inflammation	is	missed.	White	blood	cells	migrate	into	the	ischemic	area	
and	release	reactive	oxygen	species	that	cause	oxidative	damage.	
(“Inflammation”	2016).	By	damaging	the	surrounding	tissue,	the	structural	
integrity	of	the	tissue	is	compromised	and	possibly	predisposed	to	hemorrhagic	
transformations.		
It	worth	noting,	however,	that	hemorrhagic	transformations	can	occur	
independent	of	pharmacologic	intervention.	A	prospective	study	of	humans	
showed	that	69%	of	individuals	with	confirmed	cardiogenic	ischemic	infarcts	
also	had	evidence	of	hemorrhagic	transformations	3	weeks	later	(Hornig	et	al,	
1993).	One	possible	reason	for	this	phenomenon	involves	metalloproteinases.	
Metalloproteinases	are	protease	enzymes	whose	catalytic	mechanisms	involve	
metal.	In	an	analysis	of	five	humans	who	had	died	of	ischemic	infarcts	with	
hemorrhagic	complications,	researchers	noted	a	significant	increase	in	the	
expression	of	the	cleaved	form	of	metalloproteinase‐9	in	the	areas	of	the	brain	
where	hemorrhagic	transformation	was	present,	compared	to	areas	without	
hemorrhagic	transformation	(Rosell	et	al,	2008).		Metalloproteinase‐9	degrades	
type	IV	collagen,	which	is	an	integral	component	of	the	basal	lamina.	The	basal	
lamina	is	one	of	the	primary	components	of	the	basement	membrane,	which	
separates	the	endothelial	cells	of	the	blood	vessels	from	the	extracellular	matrix.	
Degradation	of	type	IV	collagen	leads	to	the	degradation	of	the	basement	
membrane,	which	leads	to	the	eventual	rupture	of	the	blood	vessels	and	a	
hemorrhagic	transformation.	The	source	of	the	metalloproteinases	seems	to	be	
neutrophils,	as	there	was	a	strong	metalloproteinase‐9	positive	neutrophil	
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infiltration	near	the	ruptured	microvessels	(metalloproteinases	are	primarily	
found	in	stromal	cells,	which	are	the	connective	tissue	cells	of	any	organ)	(Rosell	
et	al,	2008).	This	conclusion	further	supports	the	hypothesis	that	the	anti‐
inflammatory	effects	of	fluoxetine	are	one	of	the	key	factors	in	reducing	the	
infarct	volume	and	hemorrhagic	transformation	frequency.		
	
FUTURE	EXPERIMENTS	
	 In	order	to	gain	a	better	understanding	of	the	results	of	this	experiment,	
there	are	several	possible	experiments	that	can	be	performed	in	the	future.	
	
Conduction	of	the	Same	Study	for	90	Days	
	 Part	of	the	difficulty	in	analyzing	the	results	of	this	study	is	the	disparate	
duration	of	this	experiment	compared	to	previous	experiments.	Because	the	
previous	experiment	from	this	lab	was	run	for	90	days,	while	this	experiment	
was	only	run	for	14	days,	it	can	be	difficult	to	compare	the	two	studies	and	make	
any	concrete	conclusions.	In	order	to	make	the	results	comparable,	this	same	
study	could	be	repeated	for	the	full	90	days.	Once	completed,	the	results	could	
be	used	to	ascertain	whether	or	not	vitamin	C,	when	used	in	conjunction	with	
fluoxetine	and	simvastatin,	has	any	bearing	on	infarct	size.	The	results	could	also	
be	used	to	truly	discern	whether	or	not	initiating	pharmacologic	agents	at	48‐54	
hours	is	effective	and	reducing	infarct	size.	Also,	by	re‐conducting	this	
experiment	with	male	rats	again,	any	true	differences	in	gender	concerning	the	
size	of	infarcts	could	be	ascertained.		
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Comparing	Groups	Who	Receive	Simvastatin	Pre‐Stroke	with	Those	Who	Do	Not	
For	this	experiment,	the	control	group	received	simvastatin	for	7	days	
pre‐stroke	and	six	days	post‐stroke.	Although	there	was	no	discernible	effect	on	
reducing	infarct	size,	there	cannot	be	any	concrete	conclusions	drawn	from	this	
data	about	pre‐stroke	simvastatin.	Moving	forward,	a	long‐term	study	
comparing	rats	that	do	not	receive	any	pharmacologic	intervention	to	rats	that	
receive	statins	pre‐stroke	would	provide	stronger	evidence	as	to	the	efficacy	of	
pre‐stroke	treatment	with	statins.		
At	the	minimum,	an	experiment	should	be	conducted	that	would	include	
a	pre‐stroke	treatment	regimen	with	simvastatin,	followed	by	a	post‐stroke	
regimen	of	fluoxetine	and	simvastatin	for	90	days.	The	results	of	this	experiment	
would	then	at	least	be	comparable	to	the	experiment	performed	in	2015.	A	
seven	day	pre‐stroke	treatment	regimen	may	also	not	be	adequate	enough	to	
properly	assess	whether	or	not	simvastatin	administered	pre‐stroke	has	any	
efficacy.	A	longer	course	of	pre‐stroke	simvastatin	(30	days,	for	example)	may	be	
necessary	to	be	able	to	apply	the	results	to	the	typical	experience	for	adult	
humans.	
It	is	also	worth	noting	that	the	rats	that	were	used	in	this	experiment	had	
normal	cholesterol	levels.	Normally,	adult	humans	are	prescribed	statins	when	
they	have	elevated	cholesterol	levels.	To	have	rats	with	normal	cholesterol	levels	
on	statins	pre‐stroke	does	not	accurately	reflect	the	environment	of	adult	
humans.		In	order	to	better	simulate	the	environment	that	represents	the	adult	
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human	population,	the	use	of	rats	that	have	elevated	cholesterol	levels	would	be	
warranted.	An	experiment	that	employed	two	parallel	groups	of	rats	(one	with	
elevated	cholesterol,	and	one	with	normal	cholesterol)	receiving	a	statin	pre‐
stroke	would	reveal	whether	pre‐stroke	cholesterol	levels	of	the	individuals	has	
any	affect	on	experiment	results.			
	
CONCLUSIONS	
	 The	results	of	this	experiment	generally	support	previous	results	from	
this	lab.	The	initiation	of	post‐stroke	fluoxetine,	simvastatin,	and	possibly	
vitamin	C	reduces	the	volume	of	ischemic	infarcts.	The	pharmacologic	regimen	
must	be	timed	appropriately,	however,	in	order	to	be	effective.	When	applied	too	
early,	or	too	late,	there	is	a	possible	predisposition	to	hemorrhagic	
transformations.	This	could	be	due	to	an	increase	in	vascular‐endothelial	growth	
factor,	or	an	inhibition	of	clotting	factors,	or	missing	the	window	for	inhibiting	
inflammation	and	reactive	oxygen	species.		
What	is	less	clear	is	whether	or	not	pre‐stroke	simvastatin	is	helpful	in	
reducing	the	size	of	ischemic	infarcts.	Although	analysis	of	patient	populations	
indicates	that	patients	who	are	on	statins	pre‐stroke	have	better	outcomes	post‐
stroke,	there	has	yet	to	be	a	definitive	biological	explanation	for	this	
phenomenon.	Although	the	data	from	this	experiment	indicates	that	pre‐stroke	
simvastatin	is	not	effective	in	reducing	infarct	volumes,	more	rigorous	testing	
involving	untreated	control	groups	and	extended	periods	of	experiment	time	are	
necessary	in	order	to	confirm	these	findings.		
	 82
While	the	results	of	this	experiment	are	promising,	ultimately,	more	
experimentation	is	required	in	order	to	solidify	the	conclusions	drawn	from	this	
experiment.	A	full	90	day	trial	with	an	untreated	control	group,	a	group	treated	
with	pre‐stroke	and	post‐stroke	simvastatin,	and	a	group	treated	with	pre‐
stroke	simvastatin	plus	post‐stroke	fluoxetine,	simvastatin	and	vitamin	C	would	
be	the	next	logical	step	in	determining	the	effectiveness	of	these	pharmacologic	
agents.		
To	date,	there	are	no	documented	studies	that	employ	the	pharmacologic	
triad	that	this	experiment	employed.	The	strongest	clinical	evidence	for	the	
effectiveness	for	any	of	these	agents	comes	from	the	FLAME	trial	(Chollet	et	al,	
2011).	The	FLAME	trial	was	a	double	blinded,	randomized	placebo‐controlled	
trial	that	tested	the	efficacy	of	fluoxetine	on	the	improvement	of	motor	function	
in	patients	who	had	suffered	an	ischemic	stroke.	The	researchers	measured	the	
motor	function	using	the	Fugl‐Meyer	motor	scale.	For	90	days,	59	of	the	118	
participants	received	one	20	milligram/kilogram	dose	per	day,	while	the	other	
participants	received	a	placebo.	Both	groups	underwent	rehabilitation	therapy,	
in	addition	to	pharmacologic	intervention.	Even	when	controlling	for	the	
presence	of	depressive	symptoms	and	thrombolytic	therapy,	the	data	from	the	
trial	showed	that	the	fluoxetine	group	showed	a	greater	degree	of	improvement	
over	the	placebo	group	(Chollet	et	al,	2011).	
	Because	the	current	pharmacologic	armamentarium	for	the	treatment	of	
strokes	is	so	meager,	any	potential	agent	that	could	be	of	assistance	would	have	
significant	clinical	impact.	I	believe	that	this	experiment	has	shown	the	potential	
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of	these	three	pharmacologic	agents,	and	hopefully,	future	experiments	will	
further	elucidate	the	utility	of	these	agents.		
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